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ABSTRACT 
 
Creatine and nitrates are popular dietary supplements, but little is known 
regarding their co-ingestion relative to performance, side effects and safety. The purpose 
of this study was to examine the safety and efficacy of a creatine nitrate dietary 
supplement. In a double-blind, crossover, randomized and placebo-controlled manner; 
28 apparently healthy and recreationally active men and women ingested daily 
supplements for 7 days consisting of a dextrose flavored placebo; a low dose of creatine 
nitrate and a high dose of creatine nitrate. Participants repeated the experiment with the 
alternate supplements with a 7 day washout period between each. Blood pressure, heart 
rate, blood samples, body weight, body composition, side effects questionnaires, bench 
press, leg press, and cycle ergometry performance were measured during each 
supplement period. No differences among treatments were found for any of the 
hemodynamic responses. No blood measurements exceeded normal clinical limits 
among treatments. No significant differences were observed in body composition or 
reported side effects among treatments. Pairwise comparisons found a significant 
difference between CNH and PLA, but not CNL at day 5 pre supplementation (PLA: 0.3 
[-0.8, 1.5], CNL: 0.9 [-0.3, 2.1], CNH: 2.7 [1.6, 3.9], p=0.01) and a significant decrease 
in PLA and CNL, but not CNH, at day 5 post supplementation (PLA: -4.2 [-5.7, -2.7], 
CNL: -4.2 [-5.7, -2.7], CNH: -1.8 [-3.3, -0.3], p=0.01) in bench press 1RM and in leg 
press 1RM (PLA: -13.9 [-23.1, -4.7], CNL: -13.2 [-22.3, -4.0], CNH: -6.0 [-15.2, 3.1], 
p=0.01). No other changes were noticed in any of the performance variables. Creatine 
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nitrate supplementation appears to be safe and enhance performance at the doses and for 
the duration studied. 
 iv 
 
DEDICATION 
 
I would like to dedicate this work to my parents, grandparents, aunts and uncles, 
my sister, my girlfriend Esmeralda, and all my other friends throughout the years.  
Without each of you I would not be who I am today and without your support I 
would not have been able to achieve what I have. Thank you. 
 
 v 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my committee chair, Dr. Kreider, and my committee 
members, Dr. Woodman, Dr. Fluckey, Dr. Turner, and all the other teachers I have 
known for their guidance and support throughout my education. I would like to thank 
Dr. Kreider and Dr. Earnest for providing this and numerous other research opportunities 
to the students in the ESNL. I would like to thank my friends and fellow/former staff of 
the ESNL, Deepesh Khanna, Sunday Simbo, Ryan Sowinski, Tyler Grubic, Blaise 
Collins, Majid Koozehchian, Brittany Sanchez, Aimee Reyes, Adriana Coletta, Peter 
Jung, Abigail O’Connor, Fego Galvan, Kyle Levers, Brittanie Lockard, Mike Byrd, 
Claire Baetge, Nick Barringer, many undergraduate volunteers, Chris Rasmussen, and 
Dr. Greenwood. Without your help, experience, wisdom, and time I would be much 
worse off than I am. I would like to thank all of my friends and family, without your 
support this would not have been possible.   
 vi 
 
CONTRIBUTORS AND FUNDING SOURCES 
 
Contributors 
This work was supervised by a dissertation committee consisting of Dr. Richard 
Kreider [Chair of Committee], Dr. Christopher Woodman [Committee Member], and Dr. 
James Fluckey [Committee Member] of the Department of Health and Kinesiology and 
Dr. Nancy Turner [Committee Member] of the Department of Nutrition and Food 
Science.  
Ryan Dalton served as study coordinator and assisted with data collection, 
sample analysis, data analysis, and manuscript preparation. Ryan Sowinski, Tyler 
Grubic, Blaise Collins, Brittany Sanchez, Aimee Reyes, Adriana Coletta, Majid 
Koozehchain, and Peter Jung assisted in data collection and sample analysis. Christopher 
Rasmussen serves as coordinator of the Exercise and Sport Nutrition Lab and project 
manager. Dr. Mike Greenwood assisted in research design and consultation. Dr. Peter 
Murano served as quality assurance manager. Dr. Conrad Earnest served as scientific 
liaison to the sponsor and assisted in study design, data analysis, and interpretation. 
However, Dr. Conrad Earnest was not involved in data collection or data entry and there 
were no restrictions on publication of the data or preparation of this paper. Dr. Richard 
Kreider obtained the grant, served as study PI, and assisted in the design of the study, 
data analysis, and manuscript preparation. 
 
 
 vii 
 
Funding Sources 
This study was supported by Nutrabolt (Bryan, TX) through an unrestricted 
research grant provided to Texas A&M University. The Director of Clinical Science at 
Nutrabolt assisted in study design, data analysis, and interpretation. However, the 
sponsor was not involved in data collection or data entry and there were no restrictions 
on publication of the data or preparation of this paper.  
 viii 
 
NOMENCLATURE 
 
CNH 6 gram dose of creatine nitrate group 
CNL 3 gram dose of creatine nitrate group 
PLA Placebo group 
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H
2
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H
+
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Il-8 Interleukin 8 
VO2 Oxygen consumption 
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MVC Maximal voluntary contraction 
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FAM Familiarization Session 
HR Heart rate 
SBP Systolic blood pressure 
DBP Diastolic blood pressure 
1RM One repetition maximum 
AST   Aspartate aminotransferase 
ALT   Alanine aminotransferase 
ALP   Alkaline phosphatase 
BUN   Blood urea nitrogen 
CRE   Creatinine 
CK   Creatine kinase 
LDH   Lactate dehydrogenase 
LDL   Low density lipoprotein cholesterol 
VLDL   Very low density lipoprotein cholesterol 
HDL   High density lipoprotein cholesterol 
RBC   Red blood cells 
RDW   Red blood cell distribution width 
MCV   Mean corpuscular volume 
MCH   Mean corpuscular hemoglobin 
MCHC  Mean corpuscular hemoglobin concentration 
MPV   Mean platelet volume 
WBC   White blood cells 
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DXA   Dual-energy x-ray absorptiometer 
BIA   Bioelectrical impedance analysis 
g   Gram 
kg   Kilogram 
mg   Milligram 
km   Kilometer 
J   Joule 
W   Watt 
mmol   millimole 
L   Liter 
mL   Milliliter 
min   Minute 
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CHAPTER I  
INTRODUCTION AND RATIONALE 
 
Background 
Creatine and nitrates are two popular dietary supplements. Individually, creatine 
has been shown to improve muscular strength, power, and endurance, increase muscle 
mass, and decrease fat mass more that exercise alone [1-7]. Whereas, nitrate 
supplementation has been shown to increase time to exhaustion, improve time trial 
performance, and increase average power output during endurance exercise in 
moderately trained endurance athletes [8-10].  
Studies have found no adverse effects of long term creatine supplementation 
among markers from blood and urine, reported side effects, or reported injury rates [11-
13]. In fact, recent publications have examined the potential medical benefits of creatine 
supplementation in various diseases, such as, fibromyalgia, Huntington’s, ALS, and 
Parkinson’s disease, glycemic control and insulin resistance, and protect against muscle 
mass and muscular strength and endurance loss from disuse [14-30]. 
Studies show long-term dietary nitrate consumption from whole foods is safe 
(1.2 grams per day) [31-38], and short-term studies find nitrate supplementation 
apparently safe (300 milligrams per day) [10,39]. Nitrate supplements have also been 
studied for health benefits. Research has shown nitrate supplementation can help 
improve vasodilatation, angiogenesis, mitochondrial function and synthesis, time to 
claudication pain, and glucose uptake in healthy individuals [8-10,40,41].  
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While creatine and nitrate supplementation has been studied individually, little 
research has looked at their concurrent consumption. Galvan et al. examined a 5-hour 
acute supplementation of 1.5 and 3 grams of creatine nitrate compared to creatine 
monohydrate and a dextrose placebo and a 28 day resistance training program using the 
same doses of supplements on performance and blood biomarkers [42]. Joy et al. also 
examined blood biomarkers after 28 days of 1 or 2 grams of creatine nitrate 
supplementation taken daily [43]. Jung et al. studied 2 grams of creatine nitrate as part of 
a multi-ingredient supplement acutely [44] and over an 8 week training period [45]. 
Each of these researchers concluded creatine nitrate supplementation appears safe for the 
doses and duration of supplementation used with no adverse effects reported. 
The current study examines if higher doses of creatine nitrate may have adverse 
effects on health or performance.  We compared a 3 g (CNL, 2 g creatine, 1 g nitrate) 
and 6 g (CNH, 4 g creatine, 2 g nitrate) dose of creatine nitrate to a dextrose placebo 
(PLA, 6 g dextrose) over a 7-day acute supplementation period. We hypothesized no 
adverse effects would be found in either creatine nitrate group compared to placebo for 
hemodynamic reactivity, blood markers, or reported side effects. 
Statement of the Problem 
Is 7 days of acute supplementation with a creatine nitrate supplement apparently 
safe? Will acute supplementation with creatine nitrate improve performance? 
Purpose of the Study 
The primary purpose of this study was to examine the 7 day acute effects of 
ingesting either a 6 gram per day or a 3 gram per day dose of creatine nitrate on 
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hemodynamic reactivity and changes in hepatorenal and muscle enzyme levels. The 
secondary purpose of this study was to examine the affect creatine nitrate may have on 
bench press, leg press, and cycle ergometry performance. 
General Study Overview 
This study was carried out in a randomized, crossover, double blind, placebo 
controlled manner. Participants ingested a 6 gram creatine nitrate, 3 gram creatine 
nitrate, or dextrose placebo over a seven day period with a seven day washout period 
between each supplement. On days 0, 1, 5, and 6 clinical blood markers were measured 
and side effects questionnaires were collected. On days 0 and 5 hemodynamic and 
strength testing occurred. On days 1 and 6 cycle ergometer tests were performed. 
Hypotheses 
H01: There will be no significant differences among treatments in systolic, diastolic, or 
mean arterial pressure, pulse pressure, heart rate, and rate pressure product. 
H02: There will be no significant differences among treatments in any of the clinical 
markers of health. 
H03: There will be no significant differences among treatments in hydration status. 
H04: There will be no significant differences among treatments in reported side effects. 
H05: There will be no significant differences among treatments in bench press or leg 
press performance. 
H06: There will be no significant differences among treatments in cycle ergometer 
performance. 
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Delimitations 
1. Thirty eight (n=38) male (n=20) and female (n=18) subjects were recruited for this 
study. 
2. This study included males and females ages 18-40 with at least 6 months of previous 
resistance training in bench press and leg press or squats. 
3. Participants had not consumed nutritional supplements containing creatine or nitrates 
at least 3 months prior to the study. 
4. Eligible participants took part in a familiarization session during which they were 
informed of the study protocol, filled out necessary forms including the informed 
consent and health history screening, scheduled all future testing sessions, and 
underwent practice testing on the bench press, leg press, and cycle ergometer.  
5. Subjects refrained from the consumption of NSAIDs, alcohol, and strenuous exercise 
at least 48 hours prior to each testing session. 
6. Subjects were advised to maintain a consistent diet and exercise regimen over the 
study duration (on permitted days).   
7. Subjects fasted for at least 8-h prior to each testing session.   
8. Subjects were instructed to consume all supplements according to directions 
provided, specifically ingesting one supplement package per day in the morning with 
breakfast.  
9. Subjects performed to their maximal ability on all exercise performance measures.  
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Limitations 
1. The subjects were individuals from the Texas A&M University community and 
surrounding fitness facilities that responded to recruitment fliers and emails; 
therefore the selection process was not truly random.   
2. While there may have been some variations in testing times and dietary intake, all 
efforts were made to conduct testing sessions at the same approximate time to 
account for diurnal variations.  Subjects were instructed to maintain a consistent diet 
throughout the duration of the study.   
3. Subject motivation and effort during the exercise performance testing may not have 
been 100% at each testing session.   
4. Subjects may not have followed the supplement instructions as defined during the 
familiarization session or during supplement distribution.   
5. All subjects were instructed to maintain their normal training program on permitted 
days as defined by the study protocol. However, exercise habits during the duration 
of the study may have changed and therefore changes in performance may have been 
influenced by individual differences in training rather than the assigned supplement.   
6. All equipment was calibrated according to manufacturer guidelines and all samples 
were run in duplicate to reduce likelihood of error. However, there may have been 
some innate limitations of the laboratory equipment used for data collection and 
analysis.   
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Assumptions 
1. Subjects followed the protocol that was explained to them during the 
familiarization session.   
2. Subjects answered the entrance questionnaires accurately and honestly prior to 
being accepted into the study. 
3. Subjects adhered to the 7 day supplementation protocol and the 7 day washout 
protocol each cycle as explained to them during the familiarization session.  
4. Subjects refrained from NSAIDs, alcohol, and strenuous exercise 48 hours prior 
to each testing sessions.  
5. Subjects accurately and honestly answered all side effects questionnaires. 
6. All laboratory equipment was calibrated and functioning properly prior to all 
testing sessions.   
7. The population, which the sample was drawn from, was normally distributed.   
8. The variance among the population sample was approximately equal.   
9. The sample was randomly assigned to the different supplement groups. Subjects 
and researchers remained blinded to their assigned supplement throughout the 
study.   
10. Subjects maintained a consistent dietary intake and exercise regimen (when 
permitted) throughout the duration of their respective studies.   
11. Subjects exerted 100% effort at each exercise test.  
12. Subjects fasted for 8 hours prior to each testing session and maintained a 
consistent hydration status across all testing sessions within the study protocol.  
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CHAPTER II 
REVIEW OF LITERATURE 
 
Introduction 
Creatine monohydrate is one of the most studied nutritional supplements in 
modern literature. A search on Google Scholar for creatine monohydrate returns over 
10,000 results and a simple Google search returns over 1.6 million results. Creatine 
monohydrate is probably the most popular ergogenic aid available today, with over 300 
separate items available on Google Shopping. A recent study among NCAA athletes 
found an average creatine reported use of 14% across all athletes, ranging from 0.2% to 
3.8% for female athletes and 11.1% to 29.4% for male athletes [46]. Past research has 
estimated creatine usage rates ranging from 25-78% in collegiate athletes [47].  
With any widely available product, safety and efficacy concerns have arisen over 
creatine supplements. Popular sources, such as, Wikipedia warn of potential muscle 
cramps, strains, and pulls, diarrhea, dizziness, high blood pressure, and weight gain [48] 
and the Mayo Clinic goes even further with a list of more than 50 side effects creatine 
“may cause” ranging from abnormal heart rate, aggression, and anorexia to ischemic 
stroke, metabolic acidosis, pressure to the shins, and seizures [49]. On the other hand, 
peer reviewed research has shown creatine supplementation to have no adverse effects 
and may be of health benefit to both normal and diseased populations [2,7]. 
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Creatine Metabolism 
Creatine (C4H9N3O2) is a nitrogenous compound synthesized from arginine, 
glycine, and methionine in the liver, kidney, and pancreas [50-52]. Arginine and glycine 
are catalyzed by L-arginine:glycine amidinotransferase (AGAT) to L-ornithine and 
guanidinoacetic acid (GAA) (Figure 1). GAA and S-adenosyl-L-methionine (SAM) is 
then catalyzed by S-adenosyl-L-methionine:N-guanidinoacetate methelytransferase 
(GAMT) to S-adenosyl-L-homocysteine and creatine. Through a reversible reaction, 
creatine and adenosine triphosphate (ATP) can be catalyzed by creatine kinase into 
adenosine diphosphate (ADP) and creatine phosphate. This reaction allows creatine 
phosphate to quickly provide ATP to working muscle for short durations. When working 
muscles use available ATP, converting it into ADP, creatine phosphate can quickly 
convert ADP back into ATP to continue working. This mechanism is thought to be 
creatine’s primary benefit to exercise performance enhancement. Creatine is also thought 
to influence gene expression [50], and possibly IGF-1 [53,54], myostatin [54,55], and 
testosterone [56] levels in the blood. Both creatine and creatine phosphate can be 
degraded through hydrolysis into creatinine, which is then excreted as a waste product 
through urine [57]. 
 In humans, the liver, kidney, and pancreas all have high concentrations of AGAT 
to form GAA. After which, GAMT, found in high concentrations in the liver and 
pancreas is used to form creatine. In humans, the liver is thought to be the most 
important organ for synthesizing both GAA and creatine, but is lacking in the CK 
concentrations necessary for conversion into creatine phosphate. On the other hand, high  
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       Figure 1. Creatine metabolism. Adapted from Wyss et al [57]. 
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CK concentrations are found in cardiac and skeletal muscle tissue. In fact, strong 
correlations exist for most tissues, except the liver, between the CK activity of a tissue 
and the total creatine content of the tissue. The highest levels of creatine and creatine 
phosphate are found in skeletal muscle, heart, spermatozoa, and photoreceptor cells of 
the retina, followed by the brain, brown adipose tissue, intestine, seminal vesicles, 
seminal vesicle fluid, endothelial cells, and macrophages, with low levels found in the 
lungs, spleen, kidney, liver, white adipose tissue, blood cells, and serum [57]. An 
average 70 kg human stores around 120-140 g of total creatine in their body, 
approximately 35-40% as free creatine and 60-65% as creatine phosphate, with more 
than 90% found within skeletal muscle [50,58]. 
 Through this process humans can synthesize around 1 g of creatine per day 
[52,58]. Humans also consume creatine through dietary sources. An 8 oz serving of meat 
typically has between 1.5-2.5 grams of creatine [50] and with cooking can lose between 
20-50% of the creatine content depending on temperature, cooking time, and the type 
and cut of meat [59-62]. Based on these data a typical American receives another 1 g of 
creatine per day through dietary sources [47,52,58,63]. The average conversion of 
creatine to creatinine in the human body is about 2 grams per day [52,57,58,63], which 
equals the endogenous and exogenous contributions resulting in homeostasis.  
Creatine Supplementation and Exercise Performance 
 In a landmark study, Harris et al [64], demonstrated supplementing with 5 grams 
of creatine monohydrate 4 or 6 times per day for 2 or more days resulted in increased 
creatine content of the quadriceps femoris muscle, from 126.8 mmol/kg to 148.6 
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mmol/kg. When 1 hour of hard cycling exercise for one leg was added to the protocol 
creatine content increased further, from 118.1 mmol/kg at baseline to 148.5 mmol/kg in 
the control leg to 162.2 mmol/kg in the exercised leg. This was the first study to 
demonstrate adding supplemental creatine monohydrate to the diet could increase the 
creatine and phosphocreatine content of human skeletal muscle. No ill effects or changes 
in blood profiles were noted from this supplementation protocol. 
 Soon after this study many researchers were testing if supplementing creatine 
monohydrate to the diet could enhance athletic performance. Greenhaff et al. [65] 
compared the effect of 20 grams of creatine monohydrate and 4 grams of glucose to a 24 
gram glucose placebo taken for 5 days on maximal isokinetic knee extension torque 
during 5 sets of 30 repetitions. The group taking creatine monohydrate had a 5% 
increase in total peak torque produced compared to baseline, whereas the placebo group 
had a nonsignificant decrease in performance.  
 Harris et al. [66] examined the effect 30 grams of creatine monohydrate plus 30 
grams of glucose versus a 60 gram glucose placebo, taken each day for 6 days, could 
have on running performance of trained middle distance runners. Before and after the 
supplementation protocol, participants ran 300 meters and 1000 meters 4 times with 4 
and 3 minute rest intervals, respectively, between each. The participants in the creatine 
monohydrate group experienced a significant improvement in best 300 and 1000 meters 
times, -0.3 and -2.1 seconds, in final 300 and 1000 meters times, -0.7 and -5.5 seconds, 
and in total 4 x 1000 meter time, -13.0 seconds, with no changes in the control group.  
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 During this time, a number of researchers found no significant differences 
between creatine supplemented groups and placebo for endurance performance [67-70], 
but researchers continued to find positive results for short duration high intensity 
activities [71-73]. Afterwards, research examining if creatine monohydrate could be 
used to enhance the benefit of training soon appeared. 
 Vandenberghe et al. [74] studied the effect creatine monohydrate 
supplementation could have on resistance training in college age females. The 
participants were divided between two groups; one test group received 20 grams of 
creatine monohydrate per day for 4 days and 5 grams of creatine monohydrate per day 
for 10 weeks, the placebo group received maltodextrine in the same fashion. During the 
10 week training period all participants resistance trained 1 hour three times per week. 
Supervised exercise sessions consisted of 5 sets of 12 repetitions at 70% of one 
repetition maximum on seven different exercises: leg press, leg extension, leg curl, 
squat, bench press, shoulder press, and sit ups. After the initial 4 day supplementation 
period the phosphocreatine content of muscle increased by 6%, and remained at this 
level over the 10 week period, in the test group compared to placebo. After the 10 week 
training period both groups significantly increased 1 repetition maximum strength in all 
exercises, with the test group increasing 20-25% more than placebo in the leg press, leg 
extension and squat. Isokinetic arm flexion torque over 30 maximal repetitions for 5 sets 
was 11-25% higher across each set for the creatine group compared to placebo. At the 
end of the 10 weeks fat free mass increased significantly more for the creatine group 
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versus placebo, 5.8% vs. 3.7%. There were no significant differences found in diet or 
reported side effects between either group. 
 Kreider et al. [5] investigated the effect 15.75 grams of creatine monohydrate per 
day, compared to placebo, would have on NCAA Division 1A football players over a 28 
day offseason training period. Participants were divided between the creatine and 
placebo groups, where both groups would consume, roughly, the same diet and engage 
in the same exercise protocol. The supervised exercise program consisted of 1-3 sets of 
2-8 repetitions at 60-95% one repetition maximum for 12 different exercises 5 hours per 
week and high intensity sprint and football agility drills 3 hours per week. No significant 
differences between groups were found in dietary intake nor blood parameters: plasma 
glucose, carbon dioxide, urea nitrogen, uric acid, total protein, albumin, alkaline 
phosphatase, sodium, potassium, chloride, calcium, ionized calcium, phosphorus, 
leukocytes, neutrophils, lymphocytes, monocytes, eosonophils, basophils, hemoglobin, 
hematocrit, total bilirubin, total iron, platelets, red blood cells, red blood cell distribution 
width, mean corpuscular volume, or mean platelet volume. Other the other hand, 
creatinine, globulin, the ratio of albumin/globulin, creatine kinase, lactate 
dehydrogenase, alanine aminotransferase, were higher after creatine supplementation 
compared to placebo. There was also a 13% increase in HDL cholesterol and a 13% 
decrease in VLDL cholesterol in the creatine group. Both groups experienced an 
increase in total mass and muscle mass, with the creatine group gaining more than 
placebo. No changes in total body water or fat mass were found. In the cycle sprint test, 
maximal sprinting for 6 seconds repeated 12 times, the creatine group performed 
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significantly more work during each of the first 5 sprints with no significant differences 
found in the remaining 7 sprints compared to the placebo group. 
 Volek et al. [75] examined creatine monohydrate supplementation versus a 
placebo over a 12 week resistance training period on changes in strength and body 
composition. Both groups underwent the same supervised periodized resistance training 
program. The creatine monohydrate group consumed 25 grams of creatine for 7 days, 
followed by 5 grams for the remaining 11 weeks. The placebo group consumed an 
equivalent amount of cellulose. After 1 week and at 12 weeks the change in fat free mass 
was significantly greater for the creatine group than placebo. Additionally, the change in 
muscle fiber cross sectional area was significantly greater for the creatine group 
compared to placebo for Type I, Type IIA, and Type IIAB muscle fibers. 
 Willoughby et al. [76] demonstrated the effect supplementing with creatine 
monohydrate compared to placebo can have on muscle protein content over 12 weeks. 
Participants were divided into a non-exercise control group, and two resistance training 
groups: a 5 gram per day creatine monohydrate groups and a 5 gram per day dextrose 
placebo group. Resistance exercise for both training groups consisted of 3 sets of 6-8 
repetitions at 85-90% 1RM 3 days per week on leg press, knee extension, and knee curl. 
After 12 weeks serum creatine was significantly elevated for the creatine monohydrate 
group by 58.93% compared to control at 4.27% and placebo at 4.43%. The change in 
total body mass, fat free mass, thigh volume, and lower body relative strength were 
significantly greater for both training groups compared to control and for the creatine 
group compared to placebo. The change in myofibrillar protein content and myosin 
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heavy chain mRNA for Type I, Type IIA, and Type IIX expression was significantly 
greater for both training groups compared to control and for the creatine group compared 
to placebo.  
Many other researchers found similar results over the years. The research, on 
average, showed a 5-15% improvement in strength and maximal work capacity after 
supplementing with creatine compared to placebo [2,6,77,78].  In a meta analysis, 
Nissen et al. [79] showed creatine supplementation resulted in a 1.09%/week increase in 
strength and a 0.36%/week increase in lean muscle mass compared to placebo. Multiple 
reviews have found around 70% of acute studies and 90% of training studies yield 
positive results due to creatine supplementation, with no studies finding negative results 
[2,6]. While most studies found few or no side effects due to creatine supplementation, 
health concerns still remained. 
Creatine Supplementation Side Effects 
 A number of long term studies arose to assess the risks associated with creatine 
supplementation. Kreider et al. [13] examined the effects of consuming creatine 
monohydrate over a 21 month period on clinical health markers in NCAA division 1 
football players undergoing training. Forty four individuals who did not take creatine 
during this period served as controls. Twelve individuals consumed creatine 
monohydrate for 0-6 months, 25 for 7-12 months, and 17 for 12-21 months. Blood and 
urine samples were taken throughout the study and analyzed for muscle and liver 
enzymes, metabolic and hematological markers, lipid profiles, electrolytes, and 
lymphocytes. Among the 54 quantitative and 15 qualitative markers assessed for each 
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group at each time point no clinically significant interactions were found. In fact, the 
only differences between the controls and any group were in sodium, chloride, and 
hematocrit, but all values were within normal ranges and appear to be of no 
physiological or clinical significance.  
 Greenwood et al. [11] measured the effect supplementing with creatine 
monohydrate could have on NCAA division 1 football players during the season on 
injury rates. Thirty eight participants consumed creatine and 34 participants not 
consuming creatine served as controls. During the season athletic trainers recorded and 
categorized injury rates. Over the season rates of cramping, heat illness/dehydration, 
muscle tightness, muscle strains, and total injuries were significantly lower for creatine 
users compared to controls. There were no differences between groups for the other 
measured variables: noncontact joint injuries, contact injuries, illness, missed practices, 
or players lost for the season.  
 One of the most common concerns with creatine supplementation is increased 
levels of creatinine, which is used to diagnose kidney problems by the medical 
community, indicating creatine may cause kidney damage. Gualano et al. [80] studied 
the effects of 10 grams per day of creatine monohydrate compared to dextrose placebo 
on kidney function in healthy sedentary males over a 3 month period. All participants 
ran on a treadmill at 70% VO2 for 40 minutes bouts, three times per week, for the 
duration of the study. At weeks 4 and 12, creatinine levels decreased for placebo, but 
remained unchanged for the creatine supplementation group. On the other hand, cystatin 
C decreased for both groups and for every individual, except one in the placebo group, 
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with no significant difference between the groups. Whereas, both creatinine and cystatin 
C can be used to estimate glomelular filtration rate of the kidneys, and hence kidney 
function, creatinine is a byproduct of creatine metabolism and cystatin C is not. This 
study indicates 1) exercise training can possibly improve kidney function and 2) creatine 
supplementation does not negatively impact kidney function.  
 In a case study, Gualano et al. [81] measured kidney function of a man, with 1 
kidney and a mildly decreased glomelular filtration rate, supplementing with creatine for 
a 35 day period. The first 5 days he consumed 20 grams of creatine monohydrate per day 
and the following 30 days he consumed 5 grams per day. Before and after the 35 day 
supplementation period chromium-EDTA measurements, the gold standard of kidney 
function measurement, found no difference between before and after creatine 
monohydrate supplementation. While serum creatinine was higher and estimated 
creatinine clearance was lower, these measures falsely indicated kidney function 
decrements.   
Creatine Supplementation Health Benefits 
Recently, publications have examined the potential health benefits of creatine 
supplementation.  Due to the performance enhancing benefits of creatine, 
supplementation with exercise tends to be better than exercise alone for preventing 
muscle and bone loss and fat accumulation found in conditions, such as osteoporosis, 
congestive heart failure, COPD, and leukemia [22,82-84].  Other health conditions seem 
to benefit from creatine supplementation directly.  Muscle wasting conditions, such as 
certain muscular dystrophies and neuropathy disorders, have been shown to benefit with 
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creatine supplementation [29,30,85].  Creatine supplementation has also demonstrated a 
potential benefit for a number of brain and nervous system disorders, fibromyalgia, 
Huntington’s, ALS, and Parkinson’s disease [14,15,17,18,24,27,28,86].  Creatine helps 
improve brain function in healthy individuals during a mentally fatiguing task [86,87] 
and may help with glycemic control and insulin resistance [20,21].  Other studies 
examined short duration cast-induced immobilization and found creatine 
supplementation to have a protective effect against muscle mass and muscular strength 
and endurance loss [25] and enhance rehabilitative strength training [88]. 
 Santos et al. [89] demonstrated creatine supplementation prior to running a 30 
kilometer race in experienced marathon runners reduces inflammatory markers. Thirty 
four experienced runners (2.5-3 hour marathon times) volunteered to participate in the 
study. The experimental group ingested 20 grams of creatine monohydrate and 60 grams 
of maltodextrine and the placebo group ingested 60 grams of maltodextrine for 5 days 
before running a 30 kilometer race. Blood samples were taken pre and 24 hours post 
race. Compared with placebo, the creatine group had 60.9% less PGE2, 33.7% less TNF-
α, and 100% less LDH change from pre to 24 hours post race. No participants 
experienced any side effects during the supplementation period or during the race. 
 Lawler et al. [90] demonstrated a direct antioxidant effect of creatine in situ, 
Sestili et al. [91] showed mouse and human cells treated with creatine had increased 
survivability compared to controls when exposed to hydrogen peroxide, and Guidi et al. 
[92] found creatine protected against reactive oxygen species mediated damage to DNA 
compared to control cells. Bender et al. [18] studied the effect of creatine 
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supplementation of the health and survival of ageing mice. Starting at 12 months of age 
81 mice were fed a standard rodent diet plus 1% creatine and 81 mice were fed an 
equicaloric standard diet. At 2 years of age mice were checked daily for health status. 
Creatine fed mice had a mean “healthy” life span 9% greater and a maximum life span 
3.5% greater than control mice. No differences in neoplasm, renal damage, or dermatitis 
were different between groups. Creatine treated mice also showed better object 
recognition memory and a lower latency to initiate exploration in a novel environment. 
Creatine Variations 
 With the success of creatine monohydrate many supplement companies have 
attempted to develop a more effective form of creatine. With the exception of anhydrous 
creatine, all other forms of creatine: creatine ethyl ester, creatine malate, creatine methyl 
ester HCL, creatine citrate, creatine malate, creatine pyruvate, creatine α-amino butyrate, 
creatine α-ketoglutarate, sodium creatine phosphate, creatine taurinate, creatine 
pyroglutamate, creatine ketoisocaproate, creatine orotate, carnitine creatinate, creatine 
decanoate, and creatine gluconate, all have less creatine content than creatine 
monohydrate, ranging from 6.3-54.3% less creatine. Even when creatine content is 
matched no alternate forms of creatine have better uptake into the muscle or 
performance enhancing benefits superior to creatine monohydrate, the only exceptions 
being when creatine monohydrate is ingested with carbohydrate, protein, or D-pinitol 
[93]. Creatine pyruvate, creatine citrate, creatine malate, creatine taurinate, creatine 
pyloglutamate, and creatine gluconate are unlikely to pose health risks to healthy 
individuals at recommended doses. Creatine phosphate, magnesium creatine chelates, 
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and creatine ethyl ester pose minimal health concerns, but creatine orotate may pose 
significant safety concerns in humans due to tumor risk [94].  
Unlike creatine monohydrate, none of the alternate forms of creatine have been 
studied as extensively and no long term studies have been conducted to assess their 
safety. Creatine nitrate is another novel form of creatine marketed as a sports enhancing 
supplement. Only two studies have been conducted to measure the effectiveness and 
safety of creatine nitrate, but extensive data exists on the effects of nitrates in the human 
body. 
Nitrate Metabolism 
 Nitrate metabolism, for our purposes, centers around the formation of nitric 
oxide. The classical model of nitric oxide formation begins with L-arginine. Nitric oxide 
synthase catalyzes the two step reaction: 2 L-arginine + 3 NADPH + 1 H
+
 + 4 O2 ⇌ 2 
citrulline + 2 nitric oxide + 4 H2O + 3 NADP
+
. Nitric oxide can then be converted, 
through a number of processes, into nitrite and nitrate. Nitrates, through nitric oxide 
metabolism or though the diet, are absorbed into the blood stream, where about 25% is 
taken up by the salivary glands. Oral bacteria convert the nitrates into nitrites. Some of 
these nitrites will be converted into nitric oxide in the stomach, but a large percentage 
will enter systemic circulation where a number of proteins and enzymes, including 
globins, cytochrome c, mitochondrial proteins, polyphenols, and vitamins C and E, 
catalyze the reduction of nitrite into nitric oxide [40,95-97] (Figure 2).   
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        Figure 2. Nitrate metabolism. Adapted from Weitzberg et al [97]. 
 
 Nitric oxide acts directly on endothelial cells causing a relaxation in vascular 
smooth muscle, inducing vasodilatation, which leads to an increased blood flow [98,99].  
Nitric oxide may also enhance muscle contractility [100] and improve mitochondrial 
function [101]. The nitrate to nitric oxide reaction is oxygen independent and may help 
improve exercise performance in a hypoxic state, more so than the oxygen dependant L-
arginine pathway [97]. 
Nitrate Supplementation and Exercise Performance 
 Humans regularly ingest nitrates in the diet through vegetable and meat sources, 
but research has found ergogenic benefits by supplementing with additional nitrate 
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sources. Larsen et al. [102] had participants ingest 0.1 mmol sodium nitrate per kilogram 
of bodyweight per day (~0.5 grams per day) for 3 days, while avoiding all foods with 
high nitrate levels. An equal amount of sodium chloride was used as the placebo control. 
Participants exercised on an electronically braked cycle ergometer before and after the 
supplementation period. When compared to the placebo, the nitrate group’s VO2 at 60-
80% VO2peak was on average 0.16 L/min lower. Gross efficiency was 1.4% higher during 
nitrate supplementation and both systolic and diastolic blood pressure was significantly 
lower, 112 versus 120 and 68 versus 74 mmHg. There were no differences found in heart 
rate, lactate, ventilation, respiratory exchange ratio, or VO2peak. 
 Another study conducted by Larsen et al. [103] using the same supplementation 
protocol found a 0.1 L/min decrease in VO2max after nitrate supplementation, with no 
change in the placebo group. There was a nonsignificant trend for time to exhaustion to 
increase with the nitrate supplementation and a significant correlation between the 
change in VO2max and the change in time to exhaustion. No changes in heart rate, 
ventilation, blood lactate, respiratory exchange ratio, cyclic guanosine monophosphate, 
plasma renin, plasma aldosterone, or plasma amino acids were found between groups. 
Submaximal VO2 was found to decrease after nitrate supplementation, but not with 
placebo. Blood pressure was unchanged before exercise, but 2 minutes post exercise 
diastolic blood pressure was significantly lower in the nitrate group [104]. Other studies 
have found similar results with decreased VO2 at sub maximal workloads indicating 
improved exercise efficiency [105-108], lower resting blood pressure [106-108], and 
equal [105] or better times to exhaustion [106,108,109]. 
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 In an interesting study, Bailey et al. [110] had participants ingest either 500 mL 
of beetroot juice (5.1 mmol nitrate) or black currant juice (negligible nitrate content) for 
6 days. Pre and post supplementation participants provided blood samples and engaged 
in low (15% MVC) and high (30% MVC) knee extension exercise. Resting blood 
pressure was lower for the nitrate group and under both exercise conditions the nitrate 
group had a lower VO2 compared to placebo. Time to exhaustion was increased 25% for 
the nitrate group compared to placebo, with no difference in heart rate or VO2 at 
exhaustion. Magnetic resonance spectroscopy was used to measure muscle metabolism 
in vivo. Phosphocreatine and ATP turnover were unchanged at rest, but phosphocreatine 
levels were higher and ATP turnover rates were lower in the nitrate group, compared to 
placebo, during exercise. No changes in pH were noticed between groups at any 
condition. This study demonstrated the reduced cost of exercise from nitrate 
supplementation may be due to a reduction in the ATP cost of muscle force production. 
 Data demonstrating a beneficial effect of nitrate supplementation for strength and 
power oriented exercise has also begun to present itself in the literature. Clifford et al. 
[111] compared a high (250 mg nitrate), low (125 mg nitrate), and placebo supplement 
on muscle soreness and recovery after 100 drop jumps conducted over 5 sets of 20 
repetitions. Pre, immediately post, 24, 48, and 72 hours post participants had muscle 
soreness, blood, counter movement jump, and maximal isometric voluntary contraction 
measured. Three doses of the assigned supplement were taken after exercise on the first 
day, with two doses taken each of the following two days. At 72 hours post exercise 
muscle soreness ratings for both treatment groups had returned to baseline, while 
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placebo was still reduced by 20% from their initial value. Counter movement jump 
recovered faster with the high dose treatment, compared to placebo, at 48 and 72 hours 
post exercise by 16.4% and 7.3% respectively. No differences between groups were 
found for maximal isometric voluntary contraction, creatine kinase, TNF-α, IL-6, or IL-
8. A couple of other studies have found similar benefits showing an improvement in 
recovery time [112,113] and work performed [114] from nitrate supplementation. 
Nitrate Supplementation Side Effects 
 Nitrates are commonly found in the diet naturally through vegetables and added 
to meats as a preservative. Nitrates are generally thought to be safe with low intake 
levels. The Joint Food and Agriculture Organization / WHO Expert Committee on Food 
Additives and the European Food Safety Authority recommend ADI limits of 3.7 
mg/kg/day for nitrate (~250 mg for a 70 kg person) [32,97]. On the other hand, the 
American Heart Association recommends the Dietary Approaches to Stop Hypertension 
(DASH) diet for cardio protective benefits [115]. The DASH diet, being high in fruits 
and vegetables, can exceed 1.2 grams of nitrate per day, ~5 times the recommended ADI 
of nitrate [37,38]. Acute studies examining the performance enhancing benefits of nitrate 
supplementation have found few side effects [9,101,116], primarily a red coloring of 
urine and stool from beetroot juice supplementation [110,111]. Most experts agree a diet 
high in vegetables and reasonable amounts of nitrate supplementation through vegetable 
sources appears to be safe [10,39,117,118]. On the other hand, it should be noted the 
LD50 of nitrite is around 100-200 mg/kg, comparable to cyanide [117].  
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 While the acute effects of nitrate supplementation appear safe, the chronic effects 
of nitrates are more debated. Carcinogenic nitrosamine compounds can form through the 
metabolism of nitrates and nitrites [32,97,119] potentially leading to various forms of 
cancer in humans. In the Shanghai Women’s Health Study, DellaValle et al. [120] 
evaluated the association between dietary nitrate consumption and colorectal cancer risk 
in over 73,000 women. Dietary nitrate consumption was estimated at baseline and over a 
mean 11 year follow-up period with vitamin C and red meat intake for colorectal cancer 
hazard ratios. No association was found between overall nitrate consumption, animal, 
plant, or preserved food source nitrate and colorectal cancer risk. When nitrate 
consumption was analyzed by vitamin C intake a strong association was found. The 
lowest quintile of nitrate intake (97.1 mg per day) having a hazard ratio of 1.00 to the 
highest quintile of nitrate intake (291.5 mg per day) having a hazard ratio of 2.45 in 
people with low vitamin C (<83.9 mg per day) intake. In people with high vitamin C 
intake (>83.9 mg per day) the association was abolished. The general consensus from 
experts is there is not enough evidence in humans to conclude an increased risk for 
cancer with increasing nitrate intake [32,97]. 
Nitrate Supplementation Health Benefits 
 Nitric oxide is a well known mediator of endothelium-dependant vasodilatation, 
and endothelium dysfunction is linked to many disease processes [121,122]. Recently, 
nitrates have been studied for their potential health benefits. As in many of the exercise 
studies mentioned previously, other studies have found nitrates reduce resting blood 
pressure by an average of 5-10 mmHg [41,103,123,124]. Studies have found nitrates, by 
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their conversion to nitric oxide, are an important antibacterial agent in the 
gastrointestinal tract [125-129]. Endothelial function, and potentially atherosclerosis, 
diabetes, and cardiovascular disease risk, improves with nitrate supplementation 
[124,130,131]. Studies have also noticed decreased platelet aggregation [124], increased 
cerebral blood flow [132], and an 18% increase in time to claudication pain in peripheral 
artery disease [41].  
 Recently, Kina-Tanada et al. [133] examined the effects of long-term nitrate 
deficiency on mice. Mice were fed nutrient identical chow, except for nitrate content. At 
3 months the low nitrate mice began to experience visceral obesity, high LDL 
cholesterol, and glucose intolerance. By 18 months the mice had increased weight gain, 
hypertension, insulin resistance, and endothelial dysfunction. At 22 months almost 40% 
of the low nitrate mice had died due to cardiovascular disease, where 100% of the 
normal nitrate mice survived. Adding sodium nitrate to the low nitrate group’s diet 
prevented these outcomes. 
Creatine Nitrate Supplementation 
 To our knowledge only four previous studies have examined supplementation 
with creatine nitrate. Joy et al. [43] investigated the safety of consuming either a 1 gram 
or 2 gram serving of creatine nitrate every day over a period of 28 days compared to a 
non-supplementation group. Whole blood cell counts and comprehensive metabolic 
profiles were analyzed before and after supplementation. They concluded creatine nitrate 
appears safe in both 1 and 2 gram per day doses for 28 days.  
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 In a two part study, Galvan et al. [42] examined the effects of 1.5 gram and 3 
gram daily servings of creatine nitrate on safety and performance, compared to 5 grams 
of creatine monohydrate and a dextrose placebo on resistance trained males. The first 
study examined seven day acute effects of creatine nitrate supplementation on heart rate, 
blood pressure, hepatorenal enzymes, muscle enzymes, and side effects over a 5 hour 
period among participants in a crossover fashion, with a seven day washout period 
between each treatment. Creatinine increased in the creatine nitrate and creatine 
monohydrate groups compared to placebo, but was not outside or normal clinical values. 
No other significant differences were observed among any of the other hepatorenal 
enzymes, muscle enzymes, heart rate, blood pressure, or reported side effects. In the 
second study participants, resistance trained males, engaged in a standardized resistance 
training program while supplementing for 28 days. The first week was a loading phase 
where participants consumed 4 doses of their prescribed supplement (1.5 grams creatine 
nitrate, 3 grams creatine nitrate, 5 grams creatine monohydrate, or placebo) each day. 
After the loading phase participants took one dose of their supplement each day for the 
remaining 21 days. Once again no significant differences in hepatorenal enzymes, 
muscle enzymes, heart rate, blood pressure, or reported side effects were found. The 
high dose creatine nitrate group experienced greater changes in bench press power and 
endurance, and in fat-free mass and lean mass compared to placebo. No other group 
differences were found. 
 Jung et al. conducted both an acute [44] and 8 week resistance training [45] study 
while administering a multi-ingredient supplement containing creatine nitrate (2 g), beta-
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alanine (3 g), arginine alpha-ketoglutarate (2 g), N-acetyl-L-tryrosine (300 mg), caffeine 
(284 mg), 15% L-dopa (15 mg), ascorbic acid (500 mg), niacin (60 mg), folic acid (50 
mg), and methylcobalamin (70 mg), with and without 30% p-synepherine (20 mg) 
compared to placebo on resistance trained male and female participants. During the 
acute crossover study [44] participants consumed one serving of the supplement during 
testing with a seven day washout period between each assigned supplement. No 
significant differences among treatments were found in heart rate, blood pressure, ECG, 
clinical blood measures, or in bench press, leg press, or Wingate performance. 
Significant increases were found in resting energy expenditure responses, participants 
reported increased optimism about performance and increased vigor and energy, and 
improved cognitive performance, assessed by Stroop test, were found after consuming 
the multi-ingredient supplement. During the 8 week study [45] participants consumed 
one serving of the same supplement each day for the duration of the study, while 
following a standardized resistance training program. No significant differences among 
groups were found in body composition, resting heart rate, blood pressure, readiness to 
perform questions, anaerobic sprint capacity, or clinical blood measures. Significant 
improvements in cognitive function and the change in bench press and leg press 1RM 
were found for the multi-ingredient supplement groups compared to placebo. No other 
group differences were found. 
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CHAPTER III 
METHODS 
 
The current report represents a study examining 7-day acute ingestion of a high 
dose (CNH) and low dose (CNL) creatine nitrate supplement. Participants ingested each 
respective supplement once a day for a 7 day period in a randomized, double blind, 
crossover manner. The study was performed at the Exercise & Sport Nutrition 
Laboratory (ESNL) at Texas A&M University after obtaining approval from Texas 
A&M University Institutional Review Board (IRB2015-0684F) and signed informed 
consent from each participant. The following describes our overall procedures for this 
study followed by a detailed methodology for each test used (see below, Testing 
Methodology). 
Participants 
Twenty-eight apparently healthy and recreationally active men and women (18 
men, 10 women, age: 21.6 ± 3.7 y, height: 172.1 ± 8.2 cm, weight: 73.4 ± 10.9 kg) were 
recruited to participate in the study. Inclusion criteria required each participant have at 
least 6 months of resistance training immediately prior to entering the study inclusive of 
performing bench press and leg press or squats. Participants were excluded from 
participation if they had a history of treatment for metabolic disease (i.e., diabetes), 
hypertension, hypotension, thyroid disease, arrhythmias, and/or cardiovascular disease; 
they were currently using any prescription medication (birth control is allowed); they 
were a pregnant or lactating female or planned to become pregnant within the next 
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month; they had a history of smoking; they drank excessively (12 drinks per week); or 
they had a recent history of creatine or nitrate supplementation within 8 weeks of the 
start of supplementation.  
Familiarization Session 
Individuals who expressed interest in the study were interview by phone, email, 
or in person to determine if they met eligibility for this study. Qualified individuals were 
invited to attend a familiarization session (FAM). During the FAM participants received 
written and verbal explanations of the study design and protocols, testing procedures and 
equipment, and blood measurements that would occur during the study.  Participants 
were able to view the facility where testing and exercise training were conducted. The 
participants read and signed informed consent statements, completed personal and 
medical histories, and were assessed for standard anthropological measurements 
including height, weight, blood pressure, and heart rate. Participants also completed a 
general health screening form which was reviewed by a registered nurse. A DXA (Dual-
Energy X-ray Absorptiometer) and BIA (Bio-electrical Impedance Analysis) were 
performed to assess body composition and water. Then participants completed the 1-RM 
(1-Repetition Maximum) and 70% endurance protocols for bench press and leg press, 
and a 4 km cycle ergometer protocol that would be used for the duration of the study. 
After the exercise testing, participants scheduled their next 12 visits: 2 testing sessions 
followed by 3 days off followed by 2 testing sessions with a 7 day washout period 
between each cycle for 3 total cycles.   
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Supplementation Protocol 
Participants were assigned in a randomized, double-blind, cross-over manner to 
one of the three supplement protocols each testing week. The supplements consisted of a 
(1) placebo (6.0 g dextrose, PLA), (2) creatine nitrate at 3.0 g (2 g creatine; 1 g.nitrate, 
CNL), or (3) creatine nitrate at 6.0 g (4 g creatine; 2 g nitrate, CNH). Nutrabolt 
International (Bryan, TX) provided all of the supplements for this study, prepared and 
packaged by Thermo-life International (Phoenix, Arizona). All supplements were 
provided in identical clear plastic bags with the only differentiating characteristic being 
the letter A, B, or C printed on the label for each bag. All supplements were 
indistinguishable from each other based on taste, texture, and appearance. All employees 
conducting testing sessions were blinded to the true identity of each supplement as were 
the participants. When consuming the supplements participants were instructed to mix 
the entire contents of the package with 16 ounces of water. 
Testing Procedures 
Participants arrived at the laboratory on days 0, 1, 5, and 6 for a total of four 
laboratory visits while on each supplement. Participants were requested to fast for 8 h 
and refrain from exercise, alcohol, and NSAIDs consumption for 48 h prior to each 
testing session. A fasting blood sample of approximately 20 ml was collected using 
standard venipuncture techniques of an antecubital vein in the arm after which 
participants completed a pre exercise side effects questionnaire.  
On days 0 and 5 (Figure 3A), after the blood sample collection, participants were 
weighed and body composition and total body water was measured via bioelectrical 
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impedance analysis (BIA). After which, participants began the hemodynamic reactivity 
test, consisting of heart rate and blood pressure readings in supine and vertical positions, 
followed by the exercise tests, consisting of bench press 1-RM and leg press 1-RM and 
bench press and leg press 70% 1-RM endurance testing. Following their respective 
treatment assignment, participants were asked to ingest a dose of their respective 
supplement. Fifteen minutes post ingestion the hemodynamic and exercise tests were 
repeated, followed by the post exercise side effects questionnaire.  
One days 1 and 6 (Figure 3B), participants ingested a dose of their respective 
supplement.  Thirty minutes post supplement, the participant performed the 4 km time 
trial cycle ergometer test.  During this test the participant was encouraged to complete a 
distance of 4 km as quickly as they could on the cycle ergometer.  After this test the 
participant completed the post exercise side effects questionnaire.  
Side effect questionnaires were completed each testing day, before and after 
exercise, for the duration of the study. The questionnaires were used both to determine 
how well participants tolerated each supplement based on any symptoms as a result of 
the supplementation and as a log to monitor the participants compliance with the 
supplementation protocol. After completing the 1
st
 bout of exercise testing on day 0 
participants were given their 1
st
 dose of their respective supplement for that week.  On 
day 1, post blood draw, the 2
nd
 dose of supplement was consumed.  After which, 
participants were given 3 more separately packaged doses with instructions to consume 
one package, mixed with water, each day for the next three days: 2, 3, & 4.  On day 5, 
participants received their 6
th
 dose of supplement immediately following the 1
st
 round of 
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exercise testing on that day.  On day 6, participants consumed their 7
th
 and final dose of 
their respective supplement immediately post blood draw.  Each 7-day period, 
participants consumed 7 total doses of their respective supplement followed by a 7-day 
washout period where no supplement was consumed nor testing performed.  After 
which, the supplementation and testing schedule began again with the participants’ next 
supplement.  This cycle was repeated a total of 3 times (Figure 4), so each participant 
participated in the testing protocol while receiving all three possible formulas used in 
this study in randomized, double-blind, cross-over manner. 
Testing Methodology 
Hemodynamic Response and Reactivity Testing 
 Participants were placed on a modified inversion table (IRONMAN Gravity 4000 
Inversion Table; Paradigm Health & Wellness, Inc., City of Industry, CA, USA) which 
allowed participants to lie supine at 0° or vertical at 180°.  Participants began and 
remained in the supine position for each test for 15 minutes.  After which, heart rate was 
taken at the radial artery and systolic and diastolic blood pressure was measured by 
listening for Korotkoff sounds from the brachial artery at the antecubital area of the 
elbow using standard stethoscopes and sphygmomanometers. Once the supine 
measurements were taken the participant was placed in the vertical position for 2 
minutes, after which heart rate and blood pressure were repeated. Mean arterial pressure 
was calculated as 1/3 systolic blood pressure plus 2/3 diastolic blood pressure [134]. 
Pulse pressure was calculated as the difference in systolic and diastolic blood pressure 
[135]. Rate pressure product was calculated as heart rate multiplied by systolic blood 
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pressure [136]. Hemodynamic reactivity was determined as the difference between 
supine and standing measurements.  
 This test was repeated twice on days 0 and 5.  Once before all exercise and 
supplementation and again 15 minutes post supplement.  The test was completed a total 
of 4 times each 7-day testing period, once before any supplements and  
three times after supplementation had begun.  Participants underwent the hemodynamic 
reactivity test a total of 12 times over the duration of the study. 
Blood Collection Procedures 
Participants provided a (8 h) fasted blood sample via venipuncture from the 
antecubital vein in the forearm according to standard phlebotomy procedures. 
Approximately 10 mL of whole blood was collected at the beginning of each testing day, 
in one 7.5 mL BD Vacutainer® serum separation tube and in one 3.5 mL BD 
Vacutainer® K2 EDTA tube (Becton, Dickinson and Company, Franklin Lakes, New 
Jersey). Both tubes were allowed to sit at room temperature for 15-min, then the 7.5 mL 
serum separation tube was centrifuged at 3500 rpm for 10-min using a 4° C refrigerated 
bench top Thermo Scientific Heraeus MegaFuge 40R Centrifuge (Thermo Electron 
North America LLC, West Palm Beach, FL, USA). Both tubes were stored at 4°C for 3-4 
hours before analysis or storage. Serum was stored at -80°C in polypropylene 
microcentrifuge tubes for later analysis. 
Blood Chemistry 
Blood serum samples were analyzed for the following: alkaline phosphatase 
(ALP), aspartate transaminase (AST), alanine transaminase (ALT), creatinine, blood 
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urea nitrogen (BUN), creatine kinase (CK), lactate dehydrogenase (LDH), glucose, total 
cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and 
triglycerides (TG) using a Cobas
®
 c111 (Roche Diagnostics, Basel, Switzerland) 
automated clinical chemistry analyzer.   
The Cobas
® 
c111 automated clinical chemistry analyzer was calibrated according 
to manufacturer guidelines. This analyzer has been known to be valid and reliable in 
previously published reports [137]. The internal quality control for the Cobas
® 
c111 was 
performed using two levels of control fluids purchased from the manufacturer to 
calibrate acceptable SD and CV values for all aforementioned assays. Samples were re-
run if the observed values were outside control values and/or clinical norms according to 
standard procedures. Prior analysis in our lab yields a test-to-test reliability of a range of 
CV from 0.4-2.4% for low control samples and 0.6-1.9% on high controls. Precision is 
between 0.8-2.4% on low controls and 0.5-1.7% on high controls. 
A complete blood count with platelet differential (hemoglobin, hematocrit, red 
blood cell counts, MCV, MCH, MCHC, RDW, white blood cell counts, lymphocytes, 
granulocytes, and mid-range absolute count (MID)) was measured using a Abbott Cell 
Dyn 1800 (Abbott Laboratories, Abbott Park, IL, USA) automated hematology analyzer. 
The internal quality control for Abbott Cell Dyn 1800 was performed using three levels 
of control fluids purchased from manufacturer to calibrate acceptable SD and CV values 
for all whole blood cell parameters. Test-to-test reliability assessment of assays 
evaluated in the study yielded mean CV’s < ±6.3% with r values > 0.9.  
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Anthropometry and Body Composition 
Standardized anthropological testing included assessments for body mass and 
height on a Healthometer Professional 500KL (Pelstar LLC, Alsip, IL, USA) self-
calibrating digital scale with an accuracy of ±0.02 kg. Whole body bone density and 
body composition (excluding cranium) was measured using a Hologic Discovery W 
Dual-Energy X-ray Absorptiometer (DXA; Hologic Inc, Waltham, MA, USA) analyzed 
with APEX Software (APEX Corporation Software, Pittsburg, PA, USA) by a trained 
technician using procedures previously described [138]. Mean test-retest reliability 
studies performed on male athletes in our lab over repeated days revealed mean 
coefficients of variation (CV) for total bone mineral content and total fat free / soft tissue 
mass of 0.31-0.45 % with a mean intraclass correlation of 0.985. On the day of each test 
the equipment was calibrated following manufacture’s guidelines. 
Total Body Water 
Total body water was determined under standardized conditions using an 
ImpediMed DF50 bioelectrical impedance analyzer (BIA, ImpediMed, San Diego, CA, 
USA). Participants were laid in a supine position where two electrodes were placed on 
the dorsal side of the right hand and two other electrodes were placed on the dorsal side 
of the right foot. The participant’s weight, height, age, and sex were entered into the BIA 
to determine total body, intracellular, and extracellular water.   
Side Effects 
The side effect questionnaire was completed both before and after each testing 
session to access side effects and monitor compliance with the supplementation protocol. 
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The questionnaire was completed a total of 24 times by each participant over the 
duration of the study; 2 times each testing day for 4 testing days per supplement for 3 
different supplements. Participants were asked to rank the frequency and severity of – 
dizziness, headache, tachycardia, heart skipping or palpitations, shortness of breath, 
nervousness, blurred vision, and unusual or adverse effects. Participants were requested 
to rank their perceived symptoms with 0 (none), 1 (minimal: 1-2/wk), 2 (slight: 3-4/wk), 
3 (occasional: 5-6/wk), 4 (frequent: 7-8/wk), or 5 (severe: 9 or more/wk).   
Strength Testing 
Bench press tests were performed using a standard isotonic Olympic bench press 
(Nebula Fitness, Versailles, OH) while leg press was determined using a hip/leg sled 
(Nebula Fitness, Versailles, OH) using standard procedures [139]. Participants warmed-
up by performing 10 repetitions at 50% of their estimated 1RM, 5 repetitions using 70% 
of their estimated 1RM, and 3 repetition using 90% of their estimated 1RM. The 
participants 1 RM was determined within approximately 5, one-repetition sets following 
the warm-up. Participants rested 2 minutes between each warm-up set and each 1RM 
attempt. Hand, seat, and foot placement positions were recorded to standardize positions 
among testing sessions. Our bench press and leg press procedures show low day-to-day 
mean coefficients of variation and high reliability in our lab (1.1%, intra-class, r=0.99).  
The endurance tests consisted of three total sets using a 70% of the 1RM measure 
at FAM load for both bench press and leg press for the duration of the study.  Two sets 
of 10 repetitions followed by one set of repetitions to failure were performed. 
Participants had a 2-minute rest period between sets. During the 2
nd
 round of strength 
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testing each day, participants only completed the final set to failure without the previous 
2 sets of 10 repetitions. Day to day test reliability of performing this endurance test in 
our lab on resistance-trained participants has yielded a standard error of measurement 
(SEM) of 92 kg, a SEM as a percent of grand mean of 4.1%, a CV of 0.34, and an 
intraclass correlation coefficient of 0.99 for 3 sets of bench press total lifting volume; 
and a SEM of 820 kg, a SEM as a percent of grand mean of 6.4%, a CV of 0.32, and an 
intraclass correlation coefficient of 0.96 for 3 sets of leg press total lifting volume. 
Strength testing was repeated on days 0 and 5 before and after supplementation 
immediately following the hemodynamic reactivity test. Participants completed the 1RM 
and endurance tests 4 times each 7-day testing period for a total of 12 times over the 
duration of the study. 
4-K Time Trial Cycle Ergometer Test 
On days 1 and 6 participants performed the 4-km time trial cycle ergometer test 
on a Lode Excalibur Sport 925900 cycle ergometer (Lode BV, Groningen, The 
Netherlands). The test began with a 3-min warm-up comprised of pedaling against a 
resistance of 25 W for the first minute, 50 W for the second minute, and 100 W for the 
third minute. Then participants completed 4 kilometers at a resistance of 4 J/kg/rev.  
They were instructed to complete the 4-km as quickly as they could and encouraged for 
the entire duration of the test. The seat height, seat position, handlebar height, and 
handlebar position were recorded for each participant to use for each testing session. A 
total of six 4-km time trials were conducted over the duration of the study: Two 4-km 
time trials while supplementing for each of three supplements. Mean test-retest 
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reliability studies performed in our lab over repeated days revealed mean CV’s for time 
to completion of 0.235 with a mean intraclass correlation of 0.850. 
Data Analysis  
 All statistical analysis was completed utilizing SPSS 22.0 (IBM Statistics, 
Chicago, IL). Study data were analyzed using a repeated measured multivariate analysis 
of variance (MANOVA). Delta change values were calculated and used to determine 
changes from baseline, which were analyzed by repeated measures multivariate analysis 
of covariance (MANCOVA). Participant baseline demographic data were analyzed using 
one-way ANOVA. Overall MANOVA effects were examined as well as MANOVA 
univariate treatment effects for certain variables when significant interactions were seen. 
Greenhouse-Geisser univariate tests of within-subjects time, treatment x time, sex x 
time, and treatment x sex x time effects and between-subjects univariate treatment, sex, 
and treatment x sex effects were reported for each variable analyzed within the 
MANOVA model. When examining hematology relative to normal clinical limits, we 
examined the frequency of changes in hematology outside of normal clinical limits from 
baseline to follow-up using a Chi-square for each treatment as follows: (1) normal at 
baseline, normal at follow-up, (2) normal at baseline, high at follow-up, (3) high at 
baseline, normal at follow-up, (4) high at baseline, high at follow-up. Data were 
considered statistically significant when the probability of type I error was 0.05 or less 
and statistical trends were considered when the probability of error ranged between p > 
0.05 to p < 0.10. When a significant treatment and/or interaction alpha level was 
observed, Fisher’s least significant difference post-hoc analysis was performed to 
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determine where significance was obtained. When a non-significant treatment and/or 
interaction alpha level was observed, analyses of mean change from baseline with 95% 
CI with Sidak adjustment were performed. Data are presented as mean ± SD and mean 
change ± 95% confidence intervals as appropriate. 
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CHAPTER IV 
RESULTS 
  
Participant Characteristics 
 Initially, 38 participants were recruited for this study, signed consent forms, and 
completed the familiarization session. Of the original 38 participants, 28 participants (18 
men, 10 women, 21.6±3.7 yr of age, 20.4±10.6% body fat, 24.7±2.9 kg/m
2
 BMI) 
completed the study (Figure 5). Four participants decided to withdraw from the study 
after the familiarization session due to time constraints. Thirty four participants were 
randomized into the three treatments. Six participants withdrew after beginning 
supplementation, one due to illness unrelated to the study, one due to a family 
emergency, and four due to time constraints. Twenty eight participants completed all 
treatments and testing sessions. Table 1 represents participant demographics. 
Primary Outcome Variables – Safety 
Hemodynamic Response and Reactivity 
Table 2 presents data from the the hemodynamic reactivity test. MANOVA 
analysis revealed overall Wilks’ Lambda treatment (p=0.93), time (p=0.001), sex 
(p=0.03), treatment x time (p=0.38), treatment x sex (p=0.71), time x sex (p=0.005), and 
treatment x time x sex (p=0.45) for systolic blood pressure (SBP), diastolic blood 
pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), heart rate (HR), and 
rate pulse product (RPP). Univariate analysis revealed significant time effects for DBP 
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(p=0.001), PP (p=0.002), HR (p=0.001), and RPP (p=0.001), sex effects for HR 
(p=0.01), and time x sex effects for SBP (p=0.02), MAP (p=0.001), and PP (p=0.01). 
 
 
 
 
         
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          Figure 5. Consort Diagram. 
        
Table 1: Participant Characteristics. 
  Total Male Female p-Level 
N 28 18 10 
 
Age (y) 21.6±3.7 21.4±3.0 22.1±4.7 0.40 
Height (m) 1.72±0.08 1.76±0.06 1.65±0.06† 0.001 
Weight (kg) 67.3±10.3 70.6±8.5 61.4±10.7† 0.001 
BMI (kg/m2) 24.7±2.9 24.9±2.9 24.5±2.8 0.63 
Fat Free Mass (kg) 53.5±10.3 59.9±6.1 41.9±4.2† 0.001 
Fat Mass (kg) 13.8±8.0 10.7±6.2 19.6±7.7† 0.001 
Body Fat (%) 20.4±10.5 14.6±7.0 30.9±7.1† 0.001 
Data are mean ± SD. p<0.05 is considered significant. (†) denotes a significant difference from 
male. 
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Table 2: Hemodynamic response.                       
  
Day 
     Treatment 0 Pre Supine 0 Pre Vertical 0 Post Supine 0 Post Vertical 5 Pre Supine 5 Pre Vertical 5 Post Supine 5 Post Vertical Mean Interaction p-Level 
Systolic Overall 113.3±8.2 113.9±9.8 113.8±8.3 114.1±10.1 114.0±8.1 114.2±9.4 113.7±9.1 113.8±10.0 113.9±9.1 Time 0.92 
Blood PLA 113.9±10.2 114.4±11.2 114.2±8.9 115.0±10.0 113.6±8.5 114.9±10.3 112.2±10.3 112.7±9.0 114.4±10.1 Treatment 0.78 
Pressure CNL 114.9±7.1 114.4±10.0 113.1±7.2 113.6±9.6 115.5±7.9 115.7±8.9 115.1±8.3 115.2±10.6 114.7±8.7 Treatment x Time 0.93 
(mm Hg) CNH 111.2±6.7 112.9±8.2 114.1±8.9 113.8±11.0 113.0±7.8 111.9±8.8 113.9±8.8 113.4±10.4 113.0±8.8 
   
 
Male 114.7±7.7 115.6±9.7 114.2±7.6 115.5±8.8 114.6±8.0 115.9±8.3 112.6±7.4 113.9±9.8 114.6±8.5 Sex 0.12 
 
Female 110.7±8.6† 110.7±9.2† 113.1±9.6 111.7±11.8 113.0±8.2 111.1±10.5† 115.9±11.5* 113.6±10.4 112.5±10.0 Time x Sex 0.02 
 
PLA M 116.7±8.9 117.0±10.6 114.9±8.7 116.6±10.0 115.1±8.7 117.2±9.5 109.4±7.0 110.9±8.0 114.7±9.2 Treatment x Sex 0.56 
 
PLA F 108.8±11.0 109.6±11.1 112.8±9.6 112.2±9.8 110.8±7.7 110.6±10.8 117.2±13.4 116.0±10.1 112.3±10.5 Treatment x Time x Sex 0.23 
 
CNL M 116.7±6.9 116.6±10.3 114.1±7.4 114.9±8.7 116.9±7.6 117.6±7.4 114.6±5.4 117.0±10.1 116.0±8.0 
   
 
CNL F 111.6±6.5 110.4±8.4 111.4±6.8 111.4±11.2 113.0±8.2 112.4±10.6 116.2±12.3 112.0±11.4 112.3±9.3 
   
 
CNH M 110.9±6.0 113.2±8.2 113.4±6.8 115.1±8.0 111.8±7.2 112.8±7.4 113.7±8.6 113.7±10.8 113.1±7.9 
    CNH F 111.8±8.2 112.2±8.6 115.2±12.2 111.4±15.1 115.2±8.9 110.4±11.2 114.2±9.5 112.8±10.3 112.9±10.4    
Diastolic Overall 72.7±8.5 75.5±8.9* 73.5±7.9 76.7±7.8* 73.5±8.7 76.6±10.1* 73.7±8.5 76.2±7.7* 74.8±8.6 Time 0.001 
Blood PLA 72.6±9.1 76.8±8.8 74.5±7.6 77.9±7.6 74.5±9.2 76.2±9.7 74.1±8.8 76.1±6.4 75.4±8.5 Treatment 0.78 
Pressure CNL 73.9±7.1 74.8±8.0 72.8±7.0 76.1±7.0 73.9±9.0 77.4±11.3 72.3±7.9 76.4±8.5 74.7±8.4 Treatment x Time 0.88 
(mm Hg) CNH 71.6±9.2 74.9±10.0 73.1±9.2 76.1±8.9 72.1±8.0 76.0±9.5 74.6±8.8 76.0±8.4 74.3±9.0 
   
 
Male 74.0±7.5 77.2±6.8 73.8±6.5 76.5±5.9 74.6±7.4 77.6±7.3 73.2±6.1 76.0±6.4 75.4±6.9 Sex 0.25 
 
Female 70.3±9.7 72.5±11.3 72.9±10.1 77.1±10.5 71.5±10.5 74.7±13.8 74.5±11.7 76.5±9.8 73.7±11.1 Time x Sex 0.051 
 
PLA M 74.1±9.5 78.9±8.1 74.7±7.0 76.9±6.6 76.7±6.5 76.8±7.1 72.9±6.0 74.9±4.4 75.7±7.1 Treatment x Sex 0.95 
 
PLA F 70.0±8.1 73.0±9.0 74.2±9.0 79.8±9.2 70.6±12.3 75.2±13.7 76.4±12.5 78.4±8.7 74.7±10.5 Treatment x Time x Sex 0.69 
 
CNL M 74.7±6.4 75.9±6.3 73.7±5.9 76.6±6.0 74.9±8.8 78.7±7.4 71.6±5.6 76.9±7.0 75.4±6.9 
   
 
CNL F 72.4±8.4 72.8±10.5 71.2±8.9 75.4±8.7 72.2±9.7 75.2±16.5 73.6±11.3 75.6±11.0 73.6±10.5 
   
 
CNH M 73.3±6.5 76.8±5.8 73.0±6.8 76.1±5.3 72.3±6.6 77.3±7.6 75.2±6.4 76.2±7.5 75.0±6.7 
    CNH F 68.6±12.6 71.6±14.7 73.2±12.8 76.0±13.6 71.8±10.6 73.6±12.3 73.4±12.4 75.6±10.3 73.0±12.1    
 
 
 
  
 46 
 
Table 2: Continued.                     
  
Day 
      Treatment 0 Pre Supine 0 Pre Vertical 0 Post Supine 0 Post Vertical 5 Pre Supine 5 Pre Vertical 5 Post Supine 5 Post Vertical Mean Interaction p-Level 
Mean Overall 99.8±7.4 101.1±8.6 100.3±7.5 101.7±8.4 100.5±7.3 101.6±8.9 100.4±8.0 101.2±8.2 100.8±8.0 Time 0.41 
Arterial PLA 100.1±8.9 101.8±9.7 101.0±7.8 102.6±7.9 100.5±7.6 102.0±9.3 99.5±9.0 100.5±7.2 101.0±8.4 Treatment 0.82 
Pressure CNL 101.2±6.5 101.2±8.7 99.7±6.4 101.1±7.8 101.6±7.1 103.0±9.0 100.9±7.6 102.3±8.4 101.4±7.7 Treatment x Time 0.91 
(mm Hg) CNH 98.0±6.4 100.2±7.5 100.4±8.4 101.2±9.7 99.4±7.2 100.0±8.4 100.8±7.7 100.9±8.9 100.1±8.0 
   
 
Male 101.2±6.7 102.8±8.0* 100.7±6.5 102.5±6.7 101.3±6.4 103.1±7.0 99.4±6.0 101.2±7.5 101.5±6.9 Sex 0.13 
 
Female 97.3±8.0† 98.0±8.9† 99.7±9.2* 100.1±10.9 99.2±8.5 99.0±11.2† 102.1±10.7* 101.2±9.4* 99.6±9.6 Time x Sex 0.01 
 
PLA M 102.5±8.0 104.3±8.9 101.5±7.3 103.3±7.5 102.3±6.5 103.7±7.6 97.3±6.0 98.9±5.7 101.7±7.4 Treatment x Sex 0.77 
 
PLA F 95.9±9.2 97.4±9.8 99.9±9.0 101.4±8.8 97.4±8.8 98.8±11.4 103.6±12.0 103.5±9.0 99.7±9.8 Treatment x Time x Sex 0.26 
 
CNL M 102.7±6.4 103.0±8.5 100.6±6.3 102.1±6.5 102.9±6.2 104.6±6.6 100.2±4.5 103.6±7.1 102.5±6.6 
   
 
CNL F 98.5±6.3 97.9±8.4 98.0±6.6 99.4±9.9 99.4±8.3 100.0±12.1 102.0±11.6 99.9±10.3 99.4±9.1 
   
 
CNH M 98.4±4.8 101.1±6.3 100.0±6.0 102.1±6.3 98.6±6.1 101.0±6.7 100.9±7.0 101.2±8.9 100.4±6.6 
     CNH F 97.4±8.9 98.7±9.5 101.2±11.8 99.6±14.2 100.7±9.0 98.1±11.1 100.6±9.3 100.4±9.5 99.6±10.2       
Pulse  Overall 40.6±7.9 38.4±8.5* 40.3±6.9 37.4±8.7* 40.5±8.4 37.6±7.8* 40.1±8.2 37.6±9.3* 39.1±8.3 Time 0.002 
Pressure PLA 41.2±9.0 37.6±8.3 39.7±7.2 37.1±10.2 39.1±9.0 38.6±8.7 38.1±8.4 36.6±8.0 38.5±8.6 Treatment 0.52 
(mm Hg) CNL 41.0±5.8 39.6±7.3 40.4±6.7 37.5±8.5 41.6±9.2 38.3±7.9 42.9±6.5 38.8±11.3 40.0±8.1 Treatment x Time 0.96 
 
CNH 39.6±8.7 37.9±9.9 41.0±7.0 37.7±7.5 40.9±7.0 35.9±6.8 39.3±8.9 37.4±8.5 38.7±8.2 
   
 
Male 40.7±7.8 38.4±8.2 40.4±6.9 39.0±9.1 40.0±9.3 38.3±8.0 39.3±7.4 37.9±10.0 39.2±8.4 Sex 0.63 
 
Female 40.4±8.4 38.3±9.1 40.3±7.2 34.6±7.3 41.5±6.5 36.5±7.5 41.4±9.4 37.1±8.2 38.7±8.2 Time x Sex 0.23 
 
PLA M 42.6±9.1 38.1±8.7 40.3±7.9 39.7±10.4 38.4±9.9 40.4±9.3 36.6±6.2 36.0±8.6 39.0±8.9 Treatment x Sex 0.25 
 
PLA F 38.8±8.8 36.6±7.8 38.6±5.8 32.4±8.3 40.2±7.6 35.4±6.8 40.8±11.3 37.6±7.3 37.6±8.2 Treatment x Time x Sex 0.69 
 
CNL M 42.0±4.6 40.7±7.2 40.4±6.2 38.3±9.4 42.0±10.8 38.9±7.3 43.0±6.8 40.1±12.3 40.7±8.3 
   
 
CNL F 39.2±7.6 37.6±7.5 40.2±7.9 36.0±6.7 40.8±5.9 37.2±9.2 42.6±6.3 36.4±9.4 38.8±7.6 
   
 
CNH M 37.6±8.2 36.4±8.6 40.4±6.7 39.0±7.6 39.4±7.2 35.4±6.9 38.4±8.0 37.4±8.8 38.0±7.7 
     CNH F 43.2±8.9 40.6±11.8 42.0±7.9 35.4±7.0 43.4±6.0 36.8±7.0 40.8±10.7 37.2±8.5 39.9±8.8       
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Table 2: Continued.                     
  
Day 
      Treatment 0 Pre Supine 0 Pre Vertical 0 Post Supine 0 Post Vertical 5 Pre Supine 5 Pre Vertical 5 Post Supine 5 Post Vertical Mean Interaction p-Level 
Heart Rate Overall 61.0±9.7 72.7±11.9* 75.5±9.3* 85.4±11.7* 59.5±9.0 73.4±11.3* 76.1±10.1* 85.7±12.6* 73.7±14.0 Time 0.001 
(BPM) PLA 61.6±10.9 72.4±14.1 75.1±9.2 85.2±11.1 57.8±8.6 72.4±11.6 77.4±10.5 85.3±13.0 73.4±14.4 Treatment 0.94 
 
CNL 61.3±10.4 72.7±10.7 77.0±9.1 87.9±12.6 59.8±7.3 74.0±10.5 73.8±9.4 83.9±13.3 73.8±13.8 Treatment x Time 0.18 
 
CNH 59.9±7.8 73.1±10.9 74.3±9.7 83.0±11.4 61.0±10.9 73.7±12.1 77.2±10.2 87.9±11.7 73.8±13.9 
   
 
Male 57.8±7.8 69.1±8.5* 75.0±9.0* 84.0±11.4* 57.8±8.9 70.6±9.6* 76.6±9.9* 85.9±11.9* 72.1±13.8 Sex 0.01 
 
Female 66.7±10.4† 79.3±14.3†* 76.2±10.0* 87.7±12.1* 62.7±8.4†* 78.4±12.4†* 75.3±10.5* 85.3±14.1* 76.4±14.0† Time x Sex 0.001 
 
PLA M 58.3±7.2 67.4±8.6 76.2±8.0 85.1±12.2 56.6±8.5 69.7±10.8 78.3±9.5 85.2±12.2 72.1±14.1 Treatment x Sex 0.84 
 
PLA F 67.6±14.0 81.2±17.9 73.0±11.1 85.3±9.4 60.0±8.6 77.2±11.8 75.6±12.4 85.4±15.0 75.7±14.8 Treatment x Time x Sex 0.36 
 
CNL M 57.8±10.4 69.4±9.0 75.3±8.9 83.7±11.3 58.1±6.4 71.8±8.5 74.6±10.2 83.4±12.7 71.8±13.4 
   
 
CNL F 67.6±7.2 78.6±11.5 80.0±9.2 95.4±11.7 62.8±8.1 78.0±12.9 72.4±8.2 84.8±14.9 77.5±14.0 
   
 
CNH M 57.2±5.1 70.3±7.9 73.6±10.2 83.3±11.4 58.7±11.5 70.2±9.8 76.9±10.1 89.2±10.5 72.4±14.1 
     CNH F 64.8±9.5 78.0±14.0 75.6±9.3 82.5±12.0 65.2±8.7 80.0±13.6 77.8±10.9 85.6±13.9 76.2±13.2       
Rate Overall 6899±1173 8261±1436* 8580±1167* 9727±1493* 6789±1137 8363±1384* 8641±1215* 9733±1590* 8374±1681 Time 0.001 
Pressure PLA 7001±1332 8248±1690 8581±1286 9793±1496 6542±941 8296±1413 8673±1376 9600±1586 8342±1742 Treatment 0.87 
Product CNL 7040±1259 8283±1227 8696±1022 9945±1432 6900±919 8553±1322 8493±1218 9644±1686 8445±1616 Treatment x Time 0.50 
(mm Hg x CNH 6658±883 8252±1405 8463±1210 9442±1556 6924±1465 8239±1445 8756±1060 9954±1528 8336±1688 
   BPM) Male 6629±983 7970±1081 8551±1030 9691±1382 6621±1097 8176±1261 8604±1105 9773±1539 8252±1632 Sex 0.10 
 
Female 7386±1339 8785±1822 8632±1400 9791±1697 7091±1164 8698±1548 8707±1411 9660±1701 8594±1747 Time x Sex 0.07 
 
PLA M 6790±842 7890±1225 8750±1024 9926±1674 6491±946 8192±1554 8572±1171 9446±1492 8258±1672 Treatment x Sex 0.94 
 
PLA F 7380±1934 8892±2239 8278±1680 9554±1149 6634±977 8483±1171 8855±1742 9877±1790 8494±1862 Treatment x Time x Sex 0.23 
 
CNL M 6757±1347 8061±1058 8579±997 9556±1042 6791±840 8431±1074 8533±1135 9730±1575 8305±1528 
   
 
CNL F 7549±935 8685±1458 8906±1086 10644±1805 7098±1065 8774±1727 8422±1418 9491±1950 8696±1745 
   
 
CNH M 6340±595 7959±1004 8324±1080 9591±1405 6581±1449 7906±1115 8706±1062 10144±1555 8194±1701 
     CNH F 7230±1052 8779±1880 8714±1441 9175±1847 7541±1348 8838±1815 8846±1109 9612±1495 8592±1644       
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.93), time (p=0.001), sex (p=0.03), treatment x time (p=0.38), treatment x sex (p=0.71), time x 
sex (p=0.005), and treatment x time x sex (p=0.45).Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 is considered significant. Statistical 
notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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However, there were no significant effects found in treatment, treatment x time, 
treatment x sex, or treatment x time x sex among any of the hemodynamic variables.  
Figures 6 through 11 presents the mean change from baseline with 95% CI;s for 
systolic blood pressure, diastolic blood pressure, mean arterial pressure, pulse pressure, 
heart rate, and rate pressure product, respectively. Analysis of mean change from 
baseline with 95% CI revealed the change in diastolic blood pressure was significantly 
higher than baseline only for PLA at day 0 post supplement vertical (p<0.05). The 
change in heart rate (p<0.05) and rate pressure product (p<0.05) was significantly higher 
for all groups at every time point except day 5 pre supplement, with no differences 
among treatments. No other significant effects were observed among the changes from 
baseline. 
Figures 12 through 17 present mean reactivity (difference from supine to 
standing) with 95% CI;s for systolic blood pressure, diastolic blood pressure, mean 
arterial pressure, pulse pressure, heart rate, and rate pressure product, respectively. 
Analysis of mean reactivity with 95% CI revealed the change in diastolic blood pressure 
was significantly higher only for PLA at baseline pre-ingestion (p<0.05) and only for 
CNL at follow-up post-ingestion (p<0.05). Mean reactivity for pulse pressure was 
significantly lower only for CNH at follow-up pre-ingestion (p<0.05). Mean reactivity 
was significantly higher for all groups at all time points for heart rate (p<0.05) and rate 
pressure product (p<0.05). No differences among treatments were observed for any of 
the measures of reactivity. These data fail to reject H01: There will be no significant  
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         Figure 6. Changes in systolic blood pressure. Data are means ± CI. p<0.05 is considered significant.. 
 
 
 
 
        
         
         
         
         
         
         
         
         
         
         
         
         
         
         Figure 7. Changes in diastolic blood pressure. Data are means ± CI. p<0.05 is considered significant. Statistical 
notations. (*) denotes a significant difference from baseline. 
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         Figure 8. Changes in mean arterial pressure. Data are means ± CI. p<0.05 is considered significant.  
 
 
 
 
        
         
         
         
         
         
         
         
         
         
         
         
         
         
         Figure 9. Changes in pulse pressure. Data are means ± CI. p<0.05 is considered significant.  
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         Figure 10. Changes in heart rate. Data are means ± CI. p<0.05 is considered significant. Statistical notations. (*) 
denotes a significant difference from baseline. 
 
 
 
 
 
       
         
         
         
         
         
         
         
         
         
         
         
         
         
         Figure 11. Changes in rate pressure product. Data are means ± CI. p<0.05 is considered significant. Statistical 
notations. (*) denotes a significant difference from baseline. 
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        Figure 12. Systolic blood pressure reactivity. Data are means ± CI. p<0.05 is considered significant.  
 
 
 
 
       
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        Figure 13. Diastolic blood pressure reactivity. Data are means ± CI. p<0.05 is considered significant. 
Statistical notations. (§) denotes a significant difference from supine to standing. 
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        Figure 14. Mean arterial pressure reactivity. Data are means ± CI. p<0.05 is considered significant.  
 
 
 
 
       
        
        
        
        
        
        
        
        
        
        
        
        
        
        Figure 15. Pulse pressure reactivity. Data are means ± CI. p<0.05 is considered significant. Statistical 
notations. (§) denotes a significant difference from supine to standing. 
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        Figure 16. Heart rate reactivity. Data are means ± CI. p<0.05 is considered significant. Statistical 
notations. (§) denotes a significant difference from supine to standing. 
 
 
 
 
       
        
        
        
        
        
        
        
        
        
        
        
        
        
        Figure 17. Rate pressure product reactivity. Data are means ± CI. p<0.05 is considered significant. 
Statistical notations. (§) denotes a significant difference from supine to standing. 
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differences among treatments in systolic or diastolic blood pressure, mean arterial 
pressure, pulse pressure, heart rate, or rate pulse product. 
 Clinical Blood Markers 
Tables 3 through 9 present results of whole blood and serum markers monitored 
in this study.  No significant overall MANOVA or univariate ANOVA interactions were 
observed among treatments in any of the analyses performed. Table 10 shows Chi square 
analysis of changes from baseline values observed. This analysis also showed no 
significant changes were observed among treatments. These data fail to reject H02: There 
will be no significant differences among treatments in any of the clinical markers of 
health. 
Body Composition 
Table 13 presents body water. MANOVA analysis revealed overall Wilks’ 
Lambda treatment (p=0.98), time (p=0.04), sex (p=0.001), treatment x time (p=0.007), 
treatment x sex (p=0.98), time x sex (p=0.15), and treatment x time x sex (p=0.005). 
Univariate analysis revealed significant time effects for extracellular water (L) (p=0.04), 
sex effects for total body water (L) (p=0.001), intracellular water (L) (p=0.001), 
extracellular water (L) (p=0.001), total body water (%) (p=0.001), intracellular water 
(%) (p=0.001), extracellular water (%) (p=0.001), and treatment x time x sex effects for 
intracellular water (L) (p=0.03),) intracellular water (%) (p=0.006), extracellular water 
(%) (p=0.006). These data fail to reject H03: There will be no significant difference 
among treatments in hydration status.
 56 
 
 
Table 3: White Blood Cell Counts.               
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
White Overall 6.29±1.18 6.33±1.03 6.48±1.18 6.22±1.09 6.35±1.09 Time 0.34 
Blood PLA 6.25±1.21 6.26±1.13 6.51±1.16 6.37±1.05 6.30±1.12 Treatment 0.97 
Cell CNL 6.27±1.19 6.51±1.06 6.35±1.25 6.31±1.00 6.39±1.03 Treatment x Time 0.64 
(K/µL) CNH 6.35±1.18 6.25±0.91 6.56±1.18 6.00±1.22 6.36±1.13 
   
 
Male 6.33±1.18 6.49±1.00 6.51±1.22 6.32±0.99 6.42±1.07 Sex 0.31 
 
Female 6.23±1.19 6.08±1.06 6.43±1.13 6.06±1.25 6.22±1.11 Time x Sex 0.62 
 
PLA M 6.43±1.09 6.34±1.18 6.69±1.21 6.52±1.11 6.46±1.12 Treatment x Sex 0.62 
 
PLA F 5.89±1.43 6.09±1.10 6.15±1.05 6.06±0.93 5.99±1.07 Treatment x Time x Sex 0.63 
 
CNL M 6.20±1.34 6.85±0.64 6.41±1.44 6.41±0.94 6.43±1.07 
   
 
CNL F 6.38±1.01 6.01±1.37 6.28±0.97 6.17±1.13 6.33±0.95 
   
 
CNH M 6.33±1.20 6.32±1.01 6.40±1.10 6.03±0.90 6.38±1.04 
    CNH F 6.39±1.20 6.13±0.75 6.83±1.33 5.94±1.69 6.33±1.28    
Lymphocyte Overall 2.29±0.60 2.34±0.63 2.43±0.60* 2.23±0.59 2.31±0.60 Time 0.006 
(K/µL) PLA 2.31±0.62 2.33±0.67 2.42±0.65 2.30±0.65 2.32±0.63 Treatment 0.84 
 
CNL 2.28±0.60 2.35±0.66 2.45±0.53 2.35±0.47 2.32±0.59 Treatment x Time 0.39 
 
CNH 2.28±0.62 2.36±0.59 2.41±0.61 2.05±0.60 2.29±0.60 
   
 
Male 2.32±0.51 2.44±0.57 2.44±0.55 2.39±0.54 2.38±0.53 Sex 0.12 
 
Female 2.24±0.75 2.19±0.70 2.41±0.68 1.96±0.58†* 2.17±0.70 Time x Sex 0.01 
 
PLA M 2.38±0.51 2.46±0.65 2.46±0.65 2.44±0.66 2.42±0.60 Treatment x Sex 0.89 
 
PLA F 2.19±0.82 2.06±0.68 2.34±0.70 2.01±0.56 2.12±0.65 Treatment x Time x Sex 0.66 
 
CNL M 2.21±0.45 2.46±0.49 2.45±0.48 2.54±0.37 2.37±0.48 
   
 
CNL F 2.38±0.79 2.19±0.85 2.46±0.63 2.08±0.48 2.21±0.74 
   
 
CNH M 2.35±0.57 2.39±0.60 2.40±0.51 2.21±0.49 2.35±0.51 
    CNH F 2.14±0.71 2.30±0.61 2.43±0.78 1.79±0.70 2.17±0.72    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.94), time (p=0.02), sex (p=0.10), treatment x time (p=0.73), treatment x 
sex (p=0.86), time x sex (p=0.36), and treatment x time x sex (p=0.96). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 3: Continued.             
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
Mid-Range Overall 0.64±0.26 0.69±0.34 0.67±0.23 0.61±0.23 0.65±0.26 Time 0.13 
(K/µL) PLA 0.61±0.20 0.67±0.25 0.67±0.27 0.62±0.22 0.64±0.23 Treatment 0.58 
 
CNL 0.65±0.31 0.73±0.46 0.67±0.22 0.67±0.23 0.67±0.30 Treatment x Time 0.66 
 
CNH 0.67±0.26 0.69±0.30 0.67±0.19 0.53±0.23 0.65±0.26 
   
 
Male 0.59±0.19 0.66±0.20 0.67±0.25 0.62±0.24 0.63±0.22 Sex 0.28 
 
Female 0.72±0.34 0.76±0.49 0.67±0.17 0.58±0.21 0.69±0.33 Time x Sex 0.16 
 
PLA M 0.62±0.21 0.68±0.26 0.68±0.32 0.63±0.22 0.65±0.25 Treatment x Sex 0.39 
 
PLA F 0.59±0.20 0.65±0.24 0.64±0.18 0.60±0.21 0.62±0.21 Treatment x Time x Sex 0.72 
 
CNL M 0.54±0.10 0.66±0.20 0.65±0.25 0.70±0.21 0.62±0.19 
   
 
CNL F 0.81±0.44 0.82±0.69 0.70±0.18 0.62±0.25 0.75±0.43 
   
 
CNH M 0.61±0.22 0.63±0.13 0.67±0.20 0.55±0.26 0.63±0.22 
    CNH F 0.76±0.31 0.79±0.46 0.68±0.18 0.51±0.17 0.68±0.31    
Granulocyte Overall 3.37±0.95 3.30±0.89 3.38±0.94 3.39±1.03 3.39±0.91 Time 0.78 
(K/µL) PLA 3.33±0.78 3.27±0.83 3.41±0.99 3.44±0.94 3.34±0.86 Treatment 0.90 
 
CNL 3.35±1.26 3.42±1.07 3.24±0.89 3.30±0.75 3.41±0.89 Treatment x Time 0.83 
 
CNH 3.43±0.81 3.22±0.77 3.49±0.95 3.41±1.32 3.43±0.98 
   
 
Male 3.43±0.96 3.39±0.75 3.40±0.96 3.30±0.94 3.41±0.88 Sex 0.71 
 
Female 3.28±0.94 3.13±1.08 3.35±0.92 3.52±1.16 3.37±0.97 Time x Sex 0.30 
 
PLA M 3.45±0.76 3.21±0.83 3.54±1.10 3.44±1.09 3.40±0.93 Treatment x Sex 0.66 
 
PLA F 3.10±0.81 3.39±0.87 3.16±0.74 3.44±0.59 3.24±0.72 Treatment x Time x Sex 0.44 
 
CNL M 3.46±1.30 3.72±0.62 3.32±0.95 3.17±0.79 3.43±0.88 
   
 
CNL F 3.20±1.25 2.99±1.45 3.13±0.84 3.49±0.69 3.38±0.93 
   
 
CNH M 3.38±0.87 3.31±0.71 3.34±0.85 3.27±0.94 3.40±0.84 
    CNH F 3.51±0.73 3.06±0.88 3.73±1.10 3.63±1.85 3.48±1.19    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.94), time (p=0.02), sex (p=0.10), treatment x time (p=0.73), treatment x 
sex (p=0.86), time x sex (p=0.36), and treatment x time x sex (p=0.96). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 4: Red Blood Cell Counts.               
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
Red Overall 4.94±0.55 4.94±0.52 4.96±0.55 4.88±0.54 4.94±0.53 Time 0.57 
Blood PLA 4.98±0.47 4.95±0.39 4.95±0.49 4.90±0.52 4.94±0.47 Treatment 0.97 
Cell CNL 4.97±0.64 4.94±0.52 4.96±0.54 4.85±0.59 4.94±0.57 Treatment x Time 0.93 
(M/µL) CNH 4.87±0.54 4.92±0.66 4.97±0.63 4.89±0.52 4.94±0.57 
   
 
Male 5.21±0.44 5.14±0.46 5.25±0.43 5.12±0.46 5.19±0.43 Sex 0.001 
 
Female 4.48±0.38 4.59±0.43 4.45±0.31 4.46±0.39 4.48±0.38† Time x Sex 0.19 
 
PLA M 5.19±0.39 5.06±0.37 5.20±0.39 5.12±0.45 5.15±0.39 Treatment x Sex 0.72 
 
PLA F 4.55±0.29 4.74±0.36 4.44±0.19 4.46±0.34 4.52±0.31 Treatment x Time x Sex 0.60 
 
CNL M 5.27±0.55 5.14±0.33 5.27±0.36 5.12±0.54 5.21±0.44 
   
 
CNL F 4.45±0.42 4.59±0.62 4.42±0.34 4.36±0.29 4.44±0.42 
   
 
CNH M 5.17±0.38 5.25±0.67 5.30±0.56 5.12±0.40 5.20±0.48 
    CNH F 4.44±0.44 4.46±0.25 4.49±0.40 4.56±0.52 4.48±0.40    
Hemoglobin Overall 14.8±1.8 14.8±1.7 14.9±1.8 14.6±1.7 14.8±1.7 Time 0.62 
(g/dl) PLA 14.9±1.8 14.8±1.4 14.9±1.8 14.6±1.7 14.8±1.6 Treatment 0.94 
 
CNL 14.9±2.0 14.7±1.7 15.0±1.6 14.7±2.0 14.8±1.8 Treatment x Time 0.96 
 
CNH 14.6±1.8 14.8±2.2 15.0±2.0 14.6±1.5 14.8±1.8 
   
 
Male 15.8±1.4 15.6±1.4 16.0±1.3 15.5±1.3 15.7±1.3 Sex 0.001 
 
Female 13.2±1.3 13.4±1.5 13.2±1.0 13.1±1.3 13.2±1.2† Time x Sex 0.48 
 
PLA M 15.7±1.4 15.3±1.1 15.8±1.2 15.4±1.2 15.6±1.2 Treatment x Sex 0.79 
 
PLA F 13.4±1.3 13.7±1.4 13.0±0.9 13.1±1.4 13.3±1.2 Treatment x Time x Sex 0.60 
 
CNL M 16.0±1.7 15.5±0.8 16.0±0.9 15.7±1.7 15.8±1.3 
   
 
CNL F 13.2±1.2 13.5±2.0 13.2±0.7 12.9±1.3 13.1±1.3 
   
 
CNH M 15.7±1.0 16.0±2.0 16.2±1.6 15.4±1.0 15.8±1.4 
    CNH F 13.0±1.5 13.0±0.9 13.4±1.4 13.4±1.2 13.2±1.2    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.99), time (p=0.008), sex (p=0.001), treatment x time (p=0.90), treatment x 
sex (p=0.99), time x sex (p=0.15), and treatment x time x sex (p=0.56). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (†) denotes a significant difference from male. 
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Table 4: Continued.             
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
Hematocrit Overall 46.1±4.8 46.0±4.6 46.1±5.1 45.2±4.8 45.9±4.8 Time 0.36 
(%) PLA 46.2±4.4 46.0±3.8 45.8±4.8 45.2±4.6 45.8±4.4 Treatment 0.96 
 
CNL 46.5±5.4 46.1±4.7 46.1±4.8 45.0±5.6 45.9±5.1 Treatment x Time 0.86 
 
CNH 45.4±4.7 45.7±5.5 46.3±5.8 45.4±4.2 46.0±4.9 
   
 
Male 48.5±3.5 47.7±3.8 48.8±3.9 47.5±3.9 48.1±3.7 Sex 0.001 
 
Female 41.9±3.7 43.0±4.6 41.4±3.1 41.3±3.5 41.8±3.7† Time x Sex 0.12 
 
PLA M 48.2±3.4 46.9±3.3 48.3±3.6 47.3±3.4 47.8±3.4 Treatment x Sex 0.75 
 
PLA F 42.3±3.6 44.2±4.3 41.0±2.5 41.0±3.8 42.1±3.5 Treatment x Time x Sex 0.65 
 
CNL M 49.2±4.3 47.7±2.6 49.0±3.3 47.6±5.0 48.4±3.7 
   
 
CNL F 41.8±3.5 43.4±6.3 41.2±2.0 40.5±3.5 41.4±4.1 
   
 
CNH M 48.1±2.6 48.5±5.3 49.3±4.8 47.6±3.4 48.3±3.9 
    CNH F 41.5±4.4 41.7±2.8 41.9±4.3 42.4±3.3 41.9±3.6    
MCV Overall 93.3±4.0 93.2±4.4 93.0±3.9 92.8±4.0 93.0±4.0 Time 0.07 
(fL) PLA 92.9±4.2 93.0±4.2 92.6±3.9 92.3±4.0 92.9±4.0 Treatment 0.81 
 
CNL 93.7±3.9 93.6±5.1 93.2±3.9 92.9±4.1 93.1±4.2 Treatment x Time 0.55 
 
CNH 93.4±4.0 93.0±4.0 93.3±4.0 93.2±4.0 93.1±4.0 
   
 
Male 93.2±3.8 92.9±3.6 93.0±3.7 92.8±3.7 92.9±3.6 Sex 0.79 
 
Female 93.6±4.4 93.7±5.5 93.0±4.3 92.7±4.5 93.3±4.7 Time x Sex 0.14 
 
PLA M 92.9±4.1 92.9±3.8 92.8±3.9 92.5±3.9 92.8±3.7 Treatment x Sex 0.95 
 
PLA F 93.0±4.6 93.2±5.3 92.3±4.3 91.8±4.3 93.1±4.6 Treatment x Time x Sex 0.95 
 
CNL M 93.6±3.7 93.1±3.9 93.1±3.8 93.0±3.7 93.0±3.6 
   
 
CNL F 94.1±4.6 94.5±7.0 93.5±4.4 92.9±4.9 93.4±5.0 
   
 
CNH M 93.2±3.7 92.6±3.3 93.2±3.7 93.0±3.7 93.0±3.6 
    CNH F 93.7±4.6 93.5±4.9 93.3±4.7 93.3±4.7 93.5±4.5    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.99), time (p=0.008), sex (p=0.001), treatment x time (p=0.90), treatment x 
sex (p=0.99), time x sex (p=0.15), and treatment x time x sex (p=0.56). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (†) denotes a significant difference from male. 
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Table 4: Continued.             
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
MCH Overall 30.0±1.3 29.9±1.5 30.2±1.4 30.0±1.2 30.0±1.3 Time 0.02 
(pg/cell) PLA 29.9±1.5 29.8±1.5 30.0±1.3 29.8±1.2 29.9±1.4 Treatment 0.72 
 
CNL 30.1±1.2 29.8±1.3 30.2±1.4 30.2±1.4 30.0±1.3 Treatment x Time 0.66 
 
CNH 30.0±1.3 30.0±1.5 30.3±1.3 29.8±1.2 30.0±1.3 
   
 
Male 30.3±1.1 30.3±1.2 30.4±1.0 30.3±1.1 30.3±1.1 Sex 0.00 
 
Female 29.5±1.5 29.1±1.5 29.7±1.8 29.4±1.4 29.5±1.6† Time x Sex 0.20 
 
PLA M 30.2±1.4 30.2±1.4 30.3±1.1 30.2±1.1 30.2±1.2 Treatment x Sex 0.91 
 
PLA F 29.3±1.5 28.9±1.5 29.3±1.5 29.2±1.3 29.4±1.5 Treatment x Time x Sex 0.68 
 
CNL M 30.3±0.8 30.2±1.1 30.4±1.0 30.6±1.0 30.2±1.0 
   
 
CNL F 29.7±1.7 29.3±1.6 29.9±2.1 29.6±1.8 29.5±1.7 
   
 
CNH M 30.4±1.0 30.5±1.3 30.5±0.8 30.1±1.1 30.3±1.1 
    CNH F 29.4±1.5 29.2±1.6 29.9±1.8 29.5±1.2 29.5±1.5    
MCHC Overall 32.1±1.0 32.0±1.3 32.4±0.9* 32.3±0.9 32.2±1.0 Time 0.007 
(g/dl) PLA 32.2±1.2 32.1±1.4 32.4±0.7 32.3±0.9 32.3±1.0 Treatment 0.98 
 
CNL 32.1±1.0 31.9±1.3 32.5±0.9 32.5±0.8 32.2±1.1 Treatment x Time 0.38 
 
CNH 32.1±1.0 32.2±1.3 32.4±1.0 32.0±0.9 32.2±1.0 
   
 
Male 32.5±0.9 32.6±1.0 32.7±0.6 32.6±0.7 32.6±0.8 Sex 0.001 
 
Female 31.5±0.9 31.1±1.2 31.9±1.0 31.8±0.9 31.6±1.1† Time x Sex 0.06 
 
PLA M 32.5±1.1 32.6±1.1 32.7±0.5 32.6±0.8 32.6±0.9 Treatment x Sex 0.94 
 
PLA F 31.6±1.0 31.1±1.3 31.7±0.5 31.8±0.8 31.6±1.0 Treatment x Time x Sex 0.92 
 
CNL M 32.4±0.8 32.3±1.0 32.7±0.7 32.9±0.5 32.5±0.9 
   
 
CNL F 31.6±1.0 31.0±1.3 32.0±1.0 31.9±0.9 31.6±1.1 
   
 
CNH M 32.6±0.8 32.9±0.9 32.7±0.6 32.3±0.6 32.6±0.7 
    CNH F 31.4±0.9 31.2±1.2 32.0±1.3 31.6±1.1 31.5±1.1    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.99), time (p=0.008), sex (p=0.001), treatment x time (p=0.90), treatment x 
sex (p=0.99), time x sex (p=0.15), and treatment x time x sex (p=0.56). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (†) denotes a significant difference from male. 
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Table 4: Continued.             
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
RBCDW Overall 13.4±1.1 13.4±1.2 13.4±1.1 13.4±1.1 13.3±1.1 Time 0.75 
(%) PLA 13.4±0.9 13.3±1.2 13.3±1.0 13.4±1.1 13.3±1.0 Treatment 0.99 
 
CNL 13.4±1.1 13.5±1.2 13.3±1.1 13.3±1.0 13.4±1.0 Treatment x Time 0.54 
 
CNH 13.4±1.3 13.4±1.3 13.5±1.2 13.6±1.2 13.4±1.2 
   
 
Male 13.1±0.7 13.0±0.6 13.1±0.7 13.2±0.7 13.1±0.7 Sex 0.002 
 
Female 13.8±1.4 14.1±1.6 13.8±1.5 13.8±1.5 13.8±1.5† Time x Sex 0.06 
 
PLA M 13.1±0.5 13.0±0.8 13.1±0.8 13.1±0.6 13.1±0.7 Treatment x Sex 0.95 
 
PLA F 13.9±1.2 14.1±1.5 13.7±1.4 14.0±1.6 13.7±1.4 Treatment x Time x Sex 0.75 
 
CNL M 13.1±0.7 13.1±0.6 13.0±0.7 13.2±0.8 13.1±0.7 
   
 
CNL F 13.8±1.5 14.1±1.7 13.8±1.5 13.6±1.4 13.8±1.4 
   
 
CNH M 13.0±0.8 12.9±0.4 13.1±0.7 13.2±0.7 13.1±0.6 
    CNH F 13.8±1.7 14.0±1.8 14.0±1.7 14.0±1.6 13.9±1.6    
Platelet  Overall 213±55 219±56 213±55 217±56 211±57 Time 0.32 
Count PLA 216±59 223±65 206±63 216±60 212±61 Treatment 0.84 
(x103/µL) CNL 202±52 214±52 216±53 214±60 208±55 Treatment x Time 0.20 
 
CNH 220±56 221±52 219±48 220±50 213±53 
   
 
Male 194±45 197±42 192±38 196±43 190±43 Sex 0.001 
 
Female 245±58 257±58 250±59 252±59 250±58† Time x Sex 0.68 
 
PLA M 190±46 196±42 186±39 193±35 189±41 Treatment x Sex 0.56 
 
PLA F 268±46 276±72 246±83 261±76 256±69 Treatment x Time x Sex 0.37 
 
CNL M 187±47 196±41 194±39 190±52 185±43 
   
 
CNL F 227±55 246±55 255±54 256±51 249±52 
   
 
CNH M 207±43 201±46 197±39 206±43 196±46 
    CNH F 239±68 251±47 249±44 241±54 245±52    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.99), time (p=0.008), sex (p=0.001), treatment x time (p=0.90), treatment x 
sex (p=0.99), time x sex (p=0.15), and treatment x time x sex (p=0.56). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (†) denotes a significant difference from male. 
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Table 4: Continued.             
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
MPV Overall 10.0±1.1 9.9±1.2 10.0±1.3 9.8±1.2 10.1±1.5 Time 0.33 
(fL) PLA 9.9±1.0 9.8±1.0 10.2±1.6 9.9±1.2 10.0±1.3 Treatment 0.95 
 
CNL 10.0±1.1 10.0±1.4 9.8±0.9 10.0±1.5 10.1±1.4 Treatment x Time 0.21 
 
CNH 10.0±1.2 9.9±1.3 9.9±1.2 9.6±1.0 10.2±1.6 
   
 
Male 10.2±1.0 10.1±1.0 10.3±1.2 10.2±1.1 10.5±1.4 Sex 0.004 
 
Female 9.6±1.1 9.5±1.4 9.4±1.2 9.1±1.1 9.4±1.2† Time x Sex 0.11 
 
PLA M 10.0±1.0 10.1±0.9 10.6±1.5 10.3±1.0 10.4±1.2 Treatment x Sex 0.79 
 
PLA F 9.6±1.1 9.1±0.9 9.3±1.4 9.0±1.2 9.3±1.1 Treatment x Time x Sex 0.34 
 
CNL M 10.3±1.1 10.2±1.0 9.9±0.7 10.4±1.4 10.4±1.3 
   
 
CNL F 9.5±1.0 9.6±1.9 9.5±1.1 9.4±1.5 9.4±1.3 
   
 
CNH M 10.3±1.0 10.1±1.2 10.2±1.2 10.0±0.9 10.5±1.7 
    CNH F 9.7±1.4 9.7±1.5 9.5±1.2 9.1±0.9 9.5±1.2    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.99), time (p=0.008), sex (p=0.001), treatment x time (p=0.90), treatment x 
sex (p=0.99), time x sex (p=0.15), and treatment x time x sex (p=0.56). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 5: Kidney Function Markers.               
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
BUN Overall 14.2±3.6 14.0±4.1 14.8±4.0 14.7±4.2 14.4±4.0 Time 0.15 
(mg/dl) PLA 14.7±4.1 13.7±4.0 14.9±3.9 14.6±4.8 14.5±4.2 Treatment 0.91 
 
CNL 13.8±3.1 13.4±3.8 14.8±4.4 15.0±4.2 14.3±3.9 Treatment x Time 0.24 
 
CNH 14.1±3.7 14.9±4.6 14.8±3.7 14.5±3.7 14.6±3.9 
   
 
Male 15.4±3.4 15.6±3.9 16.7±3.3* 16.7±3.5* 16.1±3.6 Sex 0.001 
 
Female 12.1±2.9† 11.1±2.7† 11.5±2.8† 11.2±2.7† 11.5±2.8† Time x Sex 0.01 
 
PLA M 16.3±3.6 15.2±3.7 16.8±3.2 16.9±4.2 16.3±3.7 Treatment x Sex 0.89 
 
PLA F 11.8±3.4 11.1±3.0 11.5±2.8 10.5±2.3 11.2±2.8 Treatment x Time x Sex 0.25 
 
CNL M 14.5±3.0 15.2±3.1 16.9±3.9 17.0±3.3 15.9±3.4 
   
 
CNL F 12.6±2.8 10.1±2.4 11.0±2.2 11.6±3.4 11.3±2.8 
   
 
CNH M 15.4±3.6 16.5±4.7 16.3±2.9 16.2±3.2 16.1±3.6 
    CNH F 11.8±2.6 12.0±2.7 12.0±3.4 11.5±2.4 11.8±2.7    
Creatinine Overall 0.97±0.19 0.98±0.18 0.98±0.19 0.96±0.17 0.97±0.18 Time 0.24 
(mg/dl) PLA 0.96±0.18 0.98±0.18 0.95±0.20 0.95±0.17 0.96±0.18 Treatment 0.70 
 
CNL 1.01±0.20 0.99±0.18 0.97±0.16 0.94±0.15* 0.98±0.17 Treatment x Time 0.007 
 
CNH 0.93±0.17 0.98±0.18 1.02±0.20* 0.99±0.18 0.98±0.19 
   
 
Male 1.04±0.16 1.07±0.15 1.05±0.15 1.04±0.14 1.05±0.15 Sex 0.001 
 
Female 0.83±0.17 0.83±0.11 0.85±0.19 0.82±0.11 0.83±0.15† Time x Sex 0.46 
 
PLA M 1.04±0.16 1.06±0.16 1.04±0.18 1.03±0.14 1.04±0.15 Treatment x Sex 0.82 
 
PLA F 0.81±0.14 0.83±0.12 0.79±0.10 0.79±0.12 0.80±0.12 Treatment x Time x Sex 0.43 
 
CNL M 1.08±0.15 1.08±0.16 1.04±0.14 1.01±0.12 1.05±0.14 
   
 
CNL F 0.87±0.21 0.82±0.08 0.83±0.09 0.82±0.11 0.84±0.13 
   
 
CNH M 1.00±0.16 1.07±0.15 1.07±0.13 1.07±0.15 1.05±0.15 
    CNH F 0.82±0.15 0.83±0.14 0.93±0.29 0.84±0.12 0.86±0.18    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.92), time (p=0.08), sex (p=0.001), treatment x time (p=0.23), treatment x 
sex (p=0.94), time x sex (p=0.15), and treatment x time x sex (p=0.19). Univariate ANOVA p-levels from MANOVA anlysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 5: Continued.             
  
Day 
     Treatment 0 1 5 6 Mean Interaction p-Level 
BUN/ Overall 14.9±3.5 14.4±3.8 15.2±3.2 15.4±3.7 15.0±3.6 Time 0.11 
Creatinine PLA 15.5±4.0 14.3±3.8 15.7±3.1 15.4±4.1 15.2±3.8 Treatment 0.80 
Ratio CNL 14.0±2.8 13.7±3.6 15.2±3.4 15.9±3.4* 14.7±3.4 Treatment x Time 0.03 
 
CNH 15.3±3.7 15.3±4.0 14.6±3.2 14.9±3.6 15.0±3.6 
   
 
Male 15.0±3.7 14.8±3.8 16.0±3.1* 16.3±3.6* 15.5±3.6 Sex 0.02 
 
Female 14.7±3.4 13.6±3.8 13.7±3.0† 13.9±3.3† 14.0±3.4† Time x Sex 0.01 
 
PLA M 15.9±3.7 14.5±3.5 16.2±2.8 16.5±4.1 15.8±3.6 Treatment x Sex 1.00 
 
PLA F 14.9±4.6 13.9±4.6 14.7±3.5 13.5±3.3 14.2±3.9 Treatment x Time x Sex 0.17 
 
CNL M 13.5±2.9 14.4±3.7 16.2±3.3 16.9±3.0 15.3±3.4 
   
 
CNL F 14.8±2.5 12.4±3.0 13.3±2.8 14.2±3.5 13.7±3.0 
   
 
CNH M 15.7±4.1 15.6±4.2 15.5±3.3 15.5±3.6 15.6±3.7 
    CNH F 14.5±3.0 14.6±3.7 13.1±2.7 13.9±3.4 14.0±3.2    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.92), time (p=0.08), sex (p=0.001), treatment x time (p=0.23), treatment x 
sex (p=0.94), time x sex (p=0.15), and treatment x time x sex (p=0.19). Univariate ANOVA p-levels from MANOVA anlysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 6: Liver Enzymes.                 
  
Day 
      Treatment 0 1 5 6 Mean Interaction p-Level 
ALP Overall 80.4±22.2 77.9±20.1* 81.1±21.4 79.6±20.8 80.0±21.0 Time 0.04 
(U/L) PLA 80.1±21.5 78.4±20.5 80.1±19.5 78.6±20.0 80.2±20.2 Treatment 0.99 
 
CNL 81.5±23.7 77.5±21.4 81.8±22.9 79.9±20.6 80.4±21.8 Treatment x Time 0.73 
 
CNH 79.7±22.1 77.7±19.2 81.5±22.2 80.4±22.3 79.3±21.3 
   
 
Male 84.4±22.4 81.6±19.5 84.5±19.7 83.4±20.0 82.6±20.5 Sex 0.03 
 
Female 73.4±20.3 71.2±19.8 75.0±23.1 72.7±20.7 75.1±21.2† Time x Sex 0.88 
 
PLA M 83.8±20.6 80.7±19.6 84.0±17.6 82.3±18.6 82.4±19.4 Treatment x Sex 0.80 
 
PLA F 73.3±22.5 74.3±22.7 72.9±21.7 71.9±21.7 75.9±21.3 Treatment x Time x Sex 0.68 
 
CNL M 86.7±24.0 83.7±21.7 86.2±21.4 84.7±20.8 84.6±21.7 
   
 
CNL F 72.1±21.0 66.4±16.4 73.9±24.6 71.3±18.3 72.8±20.3 
   
 
CNH M 82.5±23.6 80.4±18.2 83.2±21.0 83.3±21.7 80.8±20.7 
     CNH F 74.7±19.5 72.9±20.9 78.4±25.0 75.1±23.7 76.6±22.4       
ALT Overall 20.7±8.7 20.6±9.2 20.3±9.0 21.1±11.3 21.1±9.8 Time 0.67 
(U/L) PLA 21.5±9.5 21.1±9.1 20.5±9.1 21.0±8.4 21.5±9.1 Treatment 0.78 
 
CNL 20.9±7.1 20.7±7.3 21.5±10.6 23.1±15.7 21.7±11.1 Treatment x Time 0.64 
 
CNH 19.9±9.4 19.9±11.2 19.1±7.2 19.4±8.0 20.1±9.3 
   
 
Male 22.8±8.7 22.6±9.7 22.7±9.9 24.0±12.8 23.3±10.7 Sex 0.001 
 
Female 17.0±7.4 16.9±7.0 16.0±5.2 16.0±4.7 17.1±6.2† Time x Sex 0.37 
 
PLA M 23.1±8.5 22.3±8.1 22.6±9.6 23.4±8.3 23.1±8.7 Treatment x Sex 0.55 
 
PLA F 18.6±11.0 18.9±10.7 16.6±7.1 16.6±6.9 18.5±9.2 Treatment x Time x Sex 0.68 
 
CNL M 23.6±6.6 23.8±7.1 25.1±11.7 27.3±18.3 25.0±12.4 
   
 
CNL F 16.0±5.3 15.3±3.7 15.0±3.1 15.6±2.6 15.8±3.7 
   
 
CNH M 21.9±10.9 21.8±13.2 20.5±8.0 21.3±9.1 21.8±10.8 
     CNH F 16.3±4.8 16.5±5.0 16.6±5.0 15.9±4.0 17.0±4.3       
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.90), time (p=0.001), sex (p=0.001), treatment x time (p=0.66), treatment x 
sex (p=0.78), time x sex (p=0.98), and treatment x time x sex (p=0.87). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 6: Continued.               
  
Day 
      Treatment 0 1 5 6 Mean Interaction p-Level 
AST Overall 25.2±9.3 26.3±9.2 25.3±14.4 26.4±13.2 26.0±12.1 Time 0.65 
(U/L) PLA 25.2±9.4 27.1±8.9 26.5±17.4 27.3±11.2 26.8±12.4 Treatment 0.37 
 
CNL 28.4±10.9 28.0±9.6 25.5±16.6 27.2±17.5 27.4±14.4 Treatment x Time 0.72 
 
CNH 22.0±5.9 23.9±9.1 23.8±7.5 24.6±9.7 23.8±8.5 
   
 
Male 27.4±9.9 28.9±9.6 28.0±16.9 29.5±15.2 28.4±13.8 Sex 0.001 
 
Female 21.1±6.3 21.7±6.5 20.4±5.9 20.7±4.9 21.5±6.0† Time x Sex 0.69 
 
PLA M 26.8±10.0 28.4±8.9 29.0±21.0 29.9±12.5 28.4±14.1 Treatment x Sex 0.22 
 
PLA F 22.2±7.6 24.8±8.8 21.9±6.6 22.6±6.9 23.6±7.5 Treatment x Time x Sex 0.86 
 
CNL M 32.4±11.3 32.3±9.3 30.2±19.2 31.4±20.7 31.4±16.3 
   
 
CNL F 21.2±5.3 20.4±3.0 17.2±3.2 19.5±3.0 20.2±3.8 
   
 
CNH M 23.1±5.7 26.0±10.0 24.7±8.2 27.2±11.0 25.4±9.4 
     CNH F 19.9±6.0 20.0±5.8 22.2±6.3 19.9±3.9 20.9±5.5       
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.90), time (p=0.001), sex (p=0.001), treatment x time (p=0.66), treatment x 
sex (p=0.78), time x sex (p=0.98), and treatment x time x sex (p=0.87). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 7: Muscle Catabolism Markers.               
  
Day 
      Treatment 0 1 5 6 Mean Interaction p-Level 
CK Overall 227±268 334±306 404±1329 498±1204 371±967 Time 0.26 
(U/L) PLA 226±177 327±242 345±609 432±441 322±407 Treatment 0.60 
 
CNL 263±418 401±429 624±2196 714±1988 521±1592 Treatment x Time 0.82 
 
CNH 193±113 275±191 244±398 350±482 272±349 
   
 
Male 287±315 436±337 552±1638 675±1469 500±1181 Sex 0.03 
 
Female 120±80 152±83 138±188 181±209 133±80† Time x Sex 0.39 
 
PLA M 280±194 420±254 423±719 541±461 422±472 Treatment x Sex 0.62 
 
PLA F 129±83 158±72 204±317 235±341 132±65 Treatment x Time x Sex 0.78 
 
CNL M 346±505 530±488 914±2721 1004±2454 726±1954 
   
 
CNL F 114±63 169±100 103±50 191±116 146±96 
   
 
CNH M 236±98 357±186 320±482 479±564 356±409 
     CNH F 116±97 129±78 107±61 118±64 122±76       
LDH Overall 158±21 160±25 164±46 165±37 161±34 Time 0.38 
(U/L) PLA 158±17 157±19 163±27 162±21 159±21 Treatment 0.93 
 
CNL 158±24 159±29 167±68 173±55 163±49 Treatment x Time 0.66 
 
CNH 158±23 163±25 163±34 160±25 160±27 
   
 
Male 159±19 162±26 170±52 171±42 164±38 Sex 0.09 
 
Female 156±25 155±22 154±31 154±20 156±25 Time x Sex 0.18 
 
PLA M 160±16 158±20 168±28 166±21 162±22 Treatment x Sex 0.80 
 
PLA F 154±18 156±19 155±22 154±21 154±20 Treatment x Time x Sex 0.39 
 
CNL M 159±21 161±31 179±83 181±66 168±58 
   
 
CNL F 157±29 154±25 145±14 157±19 156±23 
   
 
CNH M 159±20 167±26 163±25 165±24 162±24 
     CNH F 156±27 155±24 162±48 151±23 158±32       
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.81), time (p=0.001), sex (p=0.10), treatment x time (p=0.55), treatment x 
sex (p=0.91), time x sex (p=0.03), and treatment x time x sex (p=0.87). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 
is considered significant. Statistical notations. (†) denotes a significant difference from male. 
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Table 8: Lipid Profile.                 
  
Day 
      Treatment 0 1 5 6 Mean Interaction p-Level 
Total-C Overall 3.92±1.03 3.84±0.92 3.82±0.92* 3.82±0.90* 3.83±0.97 Time 0.005 
(mmol/l) PLA 3.88±0.88 3.84±0.87 3.83±0.91 3.80±0.88 3.82±0.90 Treatment 0.99 
 
CNL 4.03±1.13 3.81±0.81 3.79±0.95 3.83±0.87 3.83±0.97 Treatment x Time 0.21 
 
CNH 3.86±1.08 3.85±1.08 3.84±0.93 3.82±0.98 3.82±1.04 
   
 
Male 3.84±1.10 3.76±1.04 3.85±1.10 3.86±1.06 3.80±1.09 Sex 0.77 
 
Female 4.07±0.89 3.97±0.63 3.77±0.45* 3.75±0.53* 3.88±0.69 Time x Sex 0.001 
 
PLA M 3.83±1.02 3.71±0.99 3.91±1.11 3.86±1.04 3.79±1.05 Treatment x Sex 0.99 
 
PLA F 3.98±0.58 4.08±0.56 3.69±0.36 3.69±0.50 3.87±0.54 Treatment x Time x Sex 0.22 
 
CNL M 3.92±1.13 3.81±0.97 3.82±1.15 3.85±1.02 3.80±1.07 
   
 
CNL F 4.23±1.17 3.83±0.44 3.75±0.41 3.79±0.54 3.90±0.76 
   
 
CNH M 3.78±1.20 3.76±1.20 3.82±1.08 3.86±1.17 3.79±1.17 
     CNH F 4.00±0.89 4.00±0.86 3.87±0.59 3.76±0.58 3.88±0.75       
HDL-C Overall 1.44±0.39 1.41±0.35 1.45±0.35 1.44±0.33 1.44±0.37 Time 0.48 
(mmol/l) PLA 1.43±0.36 1.43±0.37 1.43±0.32 1.45±0.34 1.44±0.36 Treatment 0.99 
 
CNL 1.49±0.46 1.38±0.30* 1.43±0.32 1.43±0.32 1.43±0.37 Treatment x Time 0.02 
 
CNH 1.40±0.36 1.41±0.38 1.49±0.42* 1.44±0.35 1.45±0.39 
   
 
Male 1.32±0.29 1.27±0.29 1.34±0.28 1.33±0.29 1.31±0.29 Sex 0.001 
 
Female 1.65±0.47 1.65±0.33 1.64±0.38 1.63±0.33 1.69±0.37† Time x Sex 0.28 
 
PLA M 1.33±0.33 1.29±0.32 1.36±0.31 1.37±0.32 1.34±0.33 Treatment x Sex 0.88 
 
PLA F 1.60±0.35 1.69±0.33 1.57±0.29 1.60±0.35 1.65±0.32 Treatment x Time x Sex 0.39 
 
CNL M 1.35±0.24 1.26±0.26 1.31±0.26 1.30±0.27 1.29±0.25 
   
 
CNL F 1.75±0.65 1.59±0.27 1.64±0.30 1.65±0.31 1.70±0.40 
   
 
CNH M 1.29±0.30 1.26±0.29 1.36±0.29 1.33±0.27 1.30±0.29 
     CNH F 1.60±0.40 1.67±0.39 1.73±0.53 1.65±0.38 1.72±0.41       
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.99), time (p=0.001), sex (p=0.001), treatment x time (p=0.62), treatment x 
sex (p=0.82), time x sex (p=0.004), and treatment x time x sex (p=0.28). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. 
p<0.05 is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 8: Continued.               
  
Day 
      Treatment 0 1 5 6 Mean Interaction p-Level 
Total-C/ Overall 2.61±1.32 2.53±1.17 2.29±0.96* 2.35±0.96* 2.77±0.77 Time 0.05 
HDL-C PLA 2.53±1.19 2.57±1.16 2.38±0.97 2.43±0.97 2.75±0.67 Treatment 0.84 
Ratio CNL 3.05±1.60 2.64±1.32 2.23±0.95 2.32±0.94 2.79±0.78 Treatment x Time 0.16 
 
CNH 2.26±1.02 2.38±1.04 2.27±0.98 2.31±0.99 2.77±0.85 
   
 
Male 2.74±1.53 2.63±1.33 2.40±1.08 2.47±1.06 2.98±0.80 Sex 0.15 
 
Female 2.38±0.76 2.35±0.80 2.11±0.65 2.15±0.72 2.37±0.50 Time x Sex 0.91 
 
PLA M 2.62±1.43 2.64±1.39 2.51±1.14 2.54±1.13 2.93±0.69 Treatment x Sex 0.34 
 
PLA F 2.37±0.59 2.44±0.61 2.14±0.49 2.23±0.59 2.41±0.46 Treatment x Time x Sex 0.79 
 
CNL M 3.41±1.81 2.87±1.50 2.42±1.12 2.56±1.06 3.02±0.81 
   
 
CNL F 2.40±0.86 2.22±0.82 1.89±0.37 1.90±0.46 2.37±0.52 
   
 
CNH M 2.19±1.10 2.38±1.10 2.26±1.03 2.31±1.02 3.01±0.90 
     CNH F 2.37±0.88 2.38±0.99 2.30±0.94 2.32±0.99 2.34±0.54       
LDL-C Overall 0.88±0.39 0.81±0.31 0.91±0.42* 0.83±0.33 2.42±1.15 Time 0.03 
(mmol/l) PLA 0.86±0.30 0.79±0.26 0.89±0.42 0.86±0.38 2.47±1.11 Treatment 0.95 
 
CNL 0.88±0.44 0.80±0.30 0.91±0.39 0.82±0.26 2.52±1.29 Treatment x Time 0.87 
 
CNH 0.91±0.44 0.83±0.36 0.93±0.45 0.81±0.35 2.28±1.03 
   
 
Male 0.85±0.42 0.81±0.30 0.95±0.41* 0.87±0.34 2.54±1.30 Sex 0.65 
 
Female 0.94±0.35 0.81±0.32 0.85±0.42 0.76±0.30 2.21±0.76 Time x Sex 0.04 
 
PLA M 0.85±0.34 0.77±0.27 0.98±0.45 0.90±0.40 2.58±1.30 Treatment x Sex 0.92 
 
PLA F 0.89±0.22 0.82±0.26 0.73±0.33 0.78±0.35 2.25±0.58 Treatment x Time x Sex 0.35 
 
CNL M 0.82±0.42 0.80±0.31 0.96±0.38 0.84±0.22 2.75±1.46 
   
 
CNL F 0.97±0.50 0.80±0.30 0.83±0.40 0.80±0.32 2.09±0.71 
   
 
CNH M 0.88±0.51 0.85±0.34 0.91±0.42 0.88±0.38 2.28±1.08 
     CNH F 0.95±0.29 0.80±0.41 0.98±0.52 0.69±0.26 2.29±0.95       
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.99), time (p=0.001), sex (p=0.001), treatment x time (p=0.62), treatment x 
sex (p=0.82), time x sex (p=0.004), and treatment x time x sex (p=0.28). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. 
p<0.05 is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 8: Continued.               
  
Day 
      Treatment 0 1 5 6 Mean Interaction p-Level 
Triglyceride Overall 2.84±0.79 2.84±0.74* 2.75±0.77 2.76±0.76* 0.86±0.37 Time 0.001 
(mmol/l) PLA 2.83±0.69 2.80±0.67 2.77±0.66 2.70±0.66 0.86±0.34 Treatment 0.99 
 
CNL 2.81±0.75 2.89±0.81 2.75±0.77 2.80±0.79 0.84±0.36 Treatment x Time 0.64 
 
CNH 2.89±0.93 2.84±0.77 2.73±0.88 2.76±0.84 0.87±0.41 
   
 
Male 2.99±0.83 3.04±0.77 2.95±0.80 2.97±0.80 0.86±0.37 Sex 0.002 
 
Female 2.57±0.63 2.48±0.55* 2.39±0.54 2.37±0.50* 0.85±0.36† Time x Sex 0.045 
 
PLA M 2.97±0.73 2.97±0.69 2.96±0.69 2.89±0.68 0.87±0.37 Treatment x Sex 0.97 
 
PLA F 2.56±0.57 2.49±0.52 2.42±0.44 2.38±0.48 0.83±0.29 Treatment x Time x Sex 0.80 
 
CNL M 2.95±0.75 3.11±0.84 2.98±0.84 3.04±0.84 0.84±0.34 
   
 
CNL F 2.56±0.72 2.49±0.60 2.35±0.41 2.36±0.48 0.85±0.39 
   
 
CNH M 3.06±1.03 3.05±0.80 2.91±0.91 2.98±0.90 0.87±0.41 
     CNH F 2.59±0.66 2.46±0.57 2.41±0.75 2.37±0.58 0.86±0.40       
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.99), time (p=0.001), sex (p=0.001), treatment x time (p=0.62), treatment x 
sex (p=0.82), time x sex (p=0.004), and treatment x time x sex (p=0.28). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. 
p<0.05 is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 9: Blood Glucose.                 
  
Day 
      Treatment 0 1 5 6 Mean Interaction p-Level 
Glucose Overall 5.10±0.52 4.89±0.40* 4.96±0.54 5.03±0.44 5.00±0.50 Time 0.04 
(mmol/l) PLA 5.09±0.34 4.85±0.39 4.84±0.48 5.05±0.38 4.97±0.42 Treatment 0.34 
 
CNL 5.16±0.69 4.84±0.37 4.85±0.32 4.97±0.47 4.97±0.52 Treatment x Time 0.06 
 
CNH 5.05±0.48 4.98±0.42 5.20±0.68 5.06±0.46 5.07±0.54 
   
 
Male 5.16±0.41 4.90±0.47 5.00±0.42 5.16±0.41 5.07±0.44 Sex 0.09 
 
Female 4.98±0.68 4.86±0.23 4.89±0.70 4.79±0.39 4.89±0.56 Time x Sex 0.09 
 
PLA M 5.19±0.33 4.81±0.46 4.90±0.56 5.18±0.34 5.03±0.46 Treatment x Sex 0.81 
 
PLA F 4.90±0.30 4.91±0.22 4.73±0.31 4.81±0.34 4.85±0.30 Treatment x Time x Sex 0.12 
 
CNL M 5.09±0.45 4.87±0.43 4.93±0.29 5.11±0.42 5.02±0.42 
   
 
CNL F 5.28±1.02 4.79±0.25 4.71±0.33 4.73±0.47 4.89±0.66 
   
 
CNH M 5.21±0.44 5.03±0.49 5.17±0.33 5.19±0.47 5.15±0.44 
     CNH F 4.77±0.44 4.87±0.24 5.24±1.09 4.83±0.36 4.93±0.66       
Data are means ± SD. Univariate ANOVA p-levels are presented for each variable. p<0.05 is considered significant. Statistical notations. (a) denotes a significant 
difference from PLA. (b) denotes a significant difference from CNL. (c) denotes a significant difference from CNH. (*) denotes a significant difference from 
baseline. (†) denotes a significant difference from male. 
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Table 10: Assessment of blood chemistry changes from baseline to day 6.           
   
PLA CNL CNH   
      N % N % N % Chi-Square 
L
ip
id
s 
&
 G
lu
co
se
 
Total-C Normal/Normal 25 89% 25 89% 25 89% 0.96 
 
Normal/High 0 0% 1 4% 1 4% 
 
 
High/High 2 7% 1 4% 1 4% 
 
 
High/Normal 1 4% 1 4% 1 4% 
 HDL-C Normal/Normal 23 82% 24 86% 22 79% 0.58 
 
Normal/High 3 11% 2 7% 4 14% 
 
 
High/High 1 4% 0 0% 2 7% 
 
 
High/Normal 1 4% 2 7% 0 0% 
 LDL-C Normal/Normal 19 68% 15 54% 22 79% 0.32 
 
Normal/High 3 11% 3 11% 3 11% 
 
 
High/High 1 4% 2 7% 2 7% 
 
 
High/Normal 5 18% 8 29% 1 4% 
 Triglyceride Normal/Normal 28 100% 28 100% 28 100% - 
 
Normal/High 0 0% 0 0% 0 0% 
 
 
High/High 0 0% 0 0% 0 0% 
 
 
High/Normal 0 0% 0 0% 0 0% 
 Glucose Normal/Normal 27 96% 25 89% 25 93% 0.46 
 
Normal/High 0 0% 0 0% 1 4% 
 
 
High/High 0 0% 0 0% 0 0% 
 
 
High/Normal 1 4% 3 11% 1 4% 
 
L
iv
er
 
ALP Normal/Normal 20 71% 17 61% 19 68% 0.78 
 
Normal/High 3 11% 2 7% 3 11% 
 
 
High/High 5 18% 8 29% 6 21% 
 
 
High/Normal 0 0% 1 4% 0 0% 
 ALT Normal/Normal 24 86% 25 89% 27 96% 0.52 
 
Normal/High 1 4% 2 7% 0 0% 
 
 
High/High 1 4% 0 0% 1 4% 
 
 
High/Normal 2 7% 1 4% 0 0% 
 AST Normal/Normal 20 71% 18 64% 25 89% 0.24 
 
Normal/High 3 11% 3 11% 2 7% 
 
 
High/High 1 4% 0 0% 0 0% 
 
 
High/Normal 4 14% 7 25% 1 4% 
 
M
u
sc
le
 
CK Normal/Normal 11 39% 10 36% 11 39% 0.89 
 
Normal/High 6 21% 6 21% 3 11% 
 
 
High/High 8 29% 7 25% 10 36% 
 
 
High/Normal 3 11% 5 18% 4 14% 
 LDH Normal/Normal 12 43% 12 43% 13 46% 0.31 
 
Normal/High 7 25% 1 4% 3 11% 
 
 
High/High 7 25% 10 36% 9 32% 
 
 
High/Normal 2 7% 5 18% 3 11% 
 
K
id
n
ey
 
BUN Normal/Normal 23 82% 25 89% 24 86% 0.31 
 
Normal/High 1 4% 3 11% 2 7% 
 
 
High/High 2 7% 0 0% 0 0% 
 
 
High/Normal 2 7% 0 0% 2 7% 
 Creatinine Normal/Normal 25 89% 25 89% 27 96% 0.23 
 
Normal/High 2 7% 0 0% 1 4% 
 
 
High/High 0 0% 0 0% 0 0% 
 
 
High/Normal 1 4% 3 11% 0 0% 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. 
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Table 11: Body water data.           
  
Day 
      Treatment 0 5 Mean Interaction p-Level 
Total Body Overall 34.6±5.3 35.5±6.5 35.1±5.9 Time 0.16 
Water PLA 34.7±5.7 34.9±5.4 34.8±5.5 Treatment 0.60 
(L) CNL 34.8±5.2 36.7±8.5 35.8±7.1 Treatment x Time 0.44 
 
CNH 34.4±5.1 34.8±4.9 34.6±4.9 
   
 
Male 37.4±3.6 38.4±5.7 37.9±4.8 Sex 0.001 
 
Female 29.6±4.0 30.2±3.7 29.9±3.9† Time x Sex 0.66 
 
PLA M 37.6±3.6 37.9±3.3 37.8±3.4 Treatment x Sex 0.82 
 
PLA F 29.5±5.1 29.5±4.2 29.5±4.5 Treatment x Time x Sex 0.95 
 
CNL M 37.7±3.4 39.9±8.7 38.8±6.6 
   
 
CNL F 29.6±3.6 30.9±4.0 30.3±3.8 
   
 
CNH M 36.9±3.9 37.4±3.4 37.2±3.6 
    CNH F 29.8±3.5 30.1±3.3 29.9±3.3    
Intracellular Overall 19.3±3.5 19.5±3.5 19.4±3.5 Time 0.39 
Water PLA 19.3±3.7 19.3±4.0 19.3±3.9 Treatment 0.77 
(L) CNL 19.4±3.6 19.8±3.4 19.6±3.5 Treatment x Time 0.20 
 
CNH 19.1±3.4 19.4±3.2 19.2±3.3 
   
 
Male 21.2±2.5 21.4±2.2 21.3±2.3 Sex 0.001 
 
Female 15.9±2.5 16.0±2.6 15.9±2.6† Time x Sex 0.61 
 
PLA M 21.2±2.5 21.6±2.1 21.4±2.3 Treatment x Sex 0.69 
 
PLA F 16.0±3.2† 14.9±2.9† 15.5±3.0 Treatment x Time x Sex 0.03 
 
CNL M 21.4±2.3 21.4±2.4 21.4±2.4 
   
 
CNL F 15.8±2.4† 16.9±2.9† 16.4±2.7 
   
 
CNH M 20.8±2.7 21.2±2.1 21.0±2.4 
    CNH F 15.9±2.1† 16.1±1.8† 16.0±1.9    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.98), time (p=0.04), sex 
(p=0.001), treatment x time (p=0.007), treatment x sex (p=0.98), time x sex (p=0.15), and treatment x time x sex 
(p=0.005). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 is 
considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a 
significant difference from male. 
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Table 11: Continued.         
  
Day 
      Treatment 0 5 Mean Interaction p-Level 
Extracellular Overall 15.4±2.1 15.5±2.0* 15.4±2.1 Time 0.04 
Water PLA 15.4±2.3 15.4±2.1 15.4±2.2 Treatment 0.96 
(L) CNL 15.4±2.1 15.6±2.1 15.5±2.1 Treatment x Time 0.96 
 
CNH 15.3±2.0 15.4±2.0 15.3±2.0 
   
 
Male 16.3±1.7 16.3±1.7 16.3±1.7 Sex 0.001 
 
Female 13.7±1.7 14.0±1.8 13.9±1.8† Time x Sex 0.09 
 
PLA M 16.4±1.7 16.2±1.7 16.3±1.7 Treatment x Sex 0.95 
 
PLA F 13.5±2.1 13.9±2.0 13.7±2.0 Treatment x Time x Sex 0.27 
 
CNL M 16.3±1.8 16.4±1.6 16.3±1.7 
   
 
CNL F 13.8±1.7 14.1±2.0 13.9±1.8 
   
 
CNH M 16.1±1.8 16.2±1.8 16.2±1.8 
    CNH F 13.8±1.5 14.0±1.6 13.9±1.5    
Total Body Overall 47.4±5.0 47.8±5.0 47.6±5.0 Time 0.14 
Water PLA 47.4±5.2 47.7±5.3 47.5±5.2 Treatment 0.82 
(%) CNL 47.7±5.2 48.3±5.4 48.0±5.2 Treatment x Time 0.68 
 
CNH 47.1±4.9 47.4±4.4 47.3±4.6 
   
 
Male 49.0±4.3 49.2±4.2 49.1±4.2 Sex 0.001 
 
Female 44.6±5.1 45.2±5.4 44.9±5.2† Time x Sex 0.54 
 
PLA M 49.0±4.2 49.5±4.1 49.3±4.1 Treatment x Sex 0.87 
 
PLA F 44.4±5.7 44.3±5.6 44.3±5.5 Treatment x Time x Sex 0.28 
 
CNL M 49.4±4.0 49.4±4.7 49.4±4.3 
   
 
CNL F 44.7±5.8 46.4±6.3 45.5±5.9 
   
 
CNH M 48.4±4.7 48.7±3.8 48.6±4.2 
    CNH F 44.7±4.4 45.0±4.5 44.9±4.3    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.98), time (p=0.04), sex 
(p=0.001), treatment x time (p=0.007), treatment x sex (p=0.98), time x sex (p=0.15), and treatment x time x sex 
(p=0.005). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 is 
considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a 
significant difference from male. 
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Table 11: Continued.         
  
Day 
      Treatment 0 5 Mean Interaction p-Level 
Intracellular Overall 55.4±3.2 55.6±3.2 55.5±3.2 Time 0.64 
Water PLA 55.5±3.0 55.5±3.3 55.5±3.2 Treatment 0.94 
(%) CNL 55.5±3.5 55.8±3.5 55.6±3.5 Treatment x Time 0.37 
 
CNH 55.3±3.2 55.5±2.9 55.4±3.0 
   
 
Male 56.5±3.1 56.8±2.8 56.6±2.9 Sex 0.001 
 
Female 53.6±2.6 53.5±3.0 53.5±2.8† Time x Sex 0.35 
 
PLA M 56.3±2.9 57.1±2.6 56.7±2.8 Treatment x Sex 0.91 
 
PLA F 53.9±2.8† 52.6±2.4†* 53.3±2.6 Treatment x Time x Sex 0.006 
 
CNL M 56.7±3.1 56.6±2.9 56.7±3.0 
   
 
CNL F 53.3±3.1† 54.3±4.3† 53.8±3.7 
   
 
CNH M 56.4±3.3 56.6±2.9 56.5±3.0 
    CNH F 53.5±2.1† 53.6±1.7† 53.5±1.8    
Extracellular Overall 44.6±3.2 44.4±3.2 44.5±3.2 Time 0.64 
Water PLA 44.5±3.0 44.5±3.3 44.5±3.2 Treatment 0.94 
(%) CNL 44.5±3.5 44.2±3.5 44.4±3.5 Treatment x Time 0.37 
 
CNH 44.7±3.2 44.5±2.9 44.6±3.0 
   
 
Male 43.5±3.1 43.3±2.8 43.4±2.9 Sex 0.001 
 
Female 46.4±2.6 46.5±3.0 46.5±2.8† Time x Sex 0.35 
 
PLA M 43.7±2.9 42.9±2.6 43.3±2.8 Treatment x Sex 0.91 
 
PLA F 46.1±2.8† 47.4±2.4†* 46.7±2.6 Treatment x Time x Sex 0.006 
 
CNL M 43.3±3.1 43.4±2.9 43.4±3.0 
   
 
CNL F 46.7±3.1† 45.7±4.3† 46.2±3.7 
   
 
CNH M 43.6±3.3 43.4±2.9 43.5±3.0 
    CNH F 46.5±2.1† 46.4±1.7† 46.5±1.8    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.98), time (p=0.04), sex 
(p=0.001), treatment x time (p=0.007), treatment x sex (p=0.98), time x sex (p=0.15), and treatment x time x sex 
(p=0.005). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 is 
considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a 
significant difference from male. 
 
Side Effects 
Table 14 presents the frequency and table 15 present the severity of side effects. 
Participants were asked to rate the frequency and severity of the following eight 
symptoms before and after testing each day: dizziness, headaches, tachycardia, heart 
palpitations, dyspnea, nervousness, blurred vision, and other symptoms. No significant 
differences for frequency or severity of symptoms were found. These data fail to reject 
H04: There will be no significant differences among treatments in reported side effects. 
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Table 12: Frequency of side effects.               
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Dizziness 0 Pre PLA 28 0 0 0 0 0 - 
Frequency Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
0 Post PLA 22 5 1 0 0 0 0.96 
 
Testing CNL 20 6 1 1 0 0 
 
  
CNH 19 7 1 1 0 0 
 
 
1 Pre PLA 27 0 1 0 0 0 0.56 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
1 Post PLA 25 3 0 0 0 0 0.35 
 
Testing CNL 24 1 3 0 0 0 
 
  
CNH 23 3 1 0 1 0 
 
 
5 Pre PLA 28 0 0 0 0 0 0.60 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
5 Post PLA 25 1 2 0 0 0 0.83 
 
Testing CNL 22 3 3 0 0 0 
 
  
CNH 24 2 2 0 0 0 
 
 
6 Pre PLA 26 1 0 1 0 0 0.32 
 
Testing CNL 26 0 2 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
6 Post PLA 24 3 0 1 0 0 0.84 
 
Testing CNL 23 2 2 1 0 0 
 
  
CNH 22 4 1 1 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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 Table 12: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Headache 0 Pre  PLA 26 1 1 0 0 0 0.33 
Frequency Testing CNL 27 0 1 0 0 0 
 
  
CNH 25 3 0 0 0 0 
 
 
0 Post PLA 16 7 2 2 0 1 0.99 
 
Testing CNL 16 7 2 1 1 1 
 
  
CNH 15 6 4 1 1 1 
 
 
1 Pre PLA 26 1 1 0 0 0 0.55 
 
Testing CNL 26 0 2 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
1 Post PLA 16 5 2 2 2 1 0.83 
 
Testing CNL 18 4 3 2 0 1 
 
  
CNH 18 5 2 3 0 0 
 
 
5 Pre PLA 25 3 0 0 0 0 0.23 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
5 Post PLA 18 5 2 2 0 1 0.65 
 
Testing CNL 19 4 3 1 0 1 
 
  
CNH 17 6 3 0 2 0 
 
 
6 Pre PLA 25 2 1 0 0 0 0.55 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
6 Post PLA 17 5 2 2 1 1 0.99 
 
Testing CNL 18 5 2 2 0 1 
 
  
CNH 16 5 2 3 1 1 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 12: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Tachycardia 0 Pre  PLA 27 1 0 0 0 0 0.12 
Frequency Testing CNL 27 0 1 0 0 0 
 
  
CNH 24 4 0 0 0 0 
 
 
0 Post PLA 16 8 4 0 0 0 0.58 
 
Testing CNL 17 6 4 1 0 0 
 
  
CNH 14 11 2 0 1 0 
 
 
1 Pre PLA 25 3 0 0 0 0 0.30 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
1 Post PLA 14 9 3 2 0 0 0.67 
 
Testing CNL 19 4 3 2 0 0 
 
  
CNH 15 9 2 1 0 1 
 
 
5 Pre PLA 25 3 0 0 0 0 0.55 
 
Testing CNL 26 1 1 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
5 Post PLA 17 7 3 1 0 0 0.87 
 
Testing CNL 18 5 4 1 0 0 
 
  
CNH 16 9 3 0 0 0 
 
 
6 Pre PLA 25 2 1 0 0 0 0.40 
 
Testing CNL 26 0 2 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
6 Post PLA 14 8 3 2 1 0 0.73 
 
Testing CNL 18 4 3 3 0 0 
 
  
CNH 17 7 1 3 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 12: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Heart 0 Pre  PLA 28 0 0 0 0 0 0.36 
Palpitations Testing CNL 28 0 0 0 0 0 
 Frequency 
 
CNH 28 0 0 0 0 0 
 
 
0 Post PLA 27 1 0 0 0 0 1.00 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
1 Pre PLA 28 0 0 0 0 0 - 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
1 Post PLA 27 1 0 0 0 0 1.00 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
5 Pre PLA 28 0 0 0 0 0 - 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
5 Post PLA 26 2 0 0 0 0 0.81 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
6 Pre PLA 28 0 0 0 0 0 - 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
6 Post PLA 27 1 0 0 0 0 0.56 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 12: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Dyspnea 0 Pre  PLA 28 0 0 0 0 0 0.36 
Frequency Testing CNL 27 1 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
0 Post PLA 23 3 2 0 0 0 0.88 
 
Testing CNL 19 5 3 1 0 0 
 
  
CNH 19 5 3 1 0 0 
 
 
1 Pre PLA 27 0 1 0 0 0 0.40 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
1 Post PLA 24 4 0 0 0 0 0.38 
 
Testing CNL 23 2 3 0 0 0 
 
  
CNH 22 4 1 1 0 0 
 
 
5 Pre PLA 27 1 0 0 0 0 0.64 
 
Testing CNL 26 2 0 0 0 0 
 
  
CNH 26 1 1 0 0 0 
 
 
5 Post PLA 24 2 1 1 0 0 0.87 
 
Testing CNL 21 3 3 1 0 0 
 
  
CNH 23 3 2 0 0 0 
 
 
6 Pre PLA 26 1 0 1 0 0 0.37 
 
Testing CNL 25 1 2 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
6 Post PLA 23 4 0 1 0 0 0.41 
 
Testing CNL 22 1 4 1 0 0 
 
  
CNH 21 2 4 1 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
 
  
 81 
 
Table 12: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Nervousness 0 Pre  PLA 26 2 0 0 0 0 0.34 
Frequency Testing CNL 27 1 0 0 0 0 
 
  
CNH 24 4 0 0 0 0 
 
 
0 Post PLA 17 5 3 2 0 1 0.98 
 
Testing CNL 15 4 3 5 0 1 
 
  
CNH 14 6 3 4 0 1 
 
 
1 Pre PLA 26 1 1 0 0 0 0.91 
 
Testing CNL 26 1 1 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
1 Post PLA 16 4 3 2 2 1 0.83 
 
Testing CNL 17 3 2 5 0 1 
 
  
CNH 17 5 3 2 1 0 
 
 
5 Pre PLA 24 4 0 0 0 0 0.20 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
5 Post PLA 18 4 3 1 1 1 0.93 
 
Testing CNL 17 5 2 3 0 1 
 
  
CNH 16 7 2 2 1 0 
 
 
6 Pre PLA 26 1 1 0 0 0 0.66 
 
Testing CNL 26 2 0 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
6 Post PLA 17 3 3 2 2 1 0.64 
 
Testing CNL 16 6 3 2 0 1 
 
  
CNH 16 3 1 6 1 1 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 12: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Blurred 0 Pre  PLA 27 1 0 0 0 0 0.12 
Vision Testing CNL 27 0 1 0 0 0 
 Frequency 
 
CNH 24 4 0 0 0 0 
 
 
0 Post PLA 17 6 5 0 0 0 0.31 
 
Testing CNL 17 2 6 2 1 0 
 
  
CNH 13 9 4 2 0 0 
 
 
1 Pre PLA 25 3 0 0 0 0 0.30 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
1 Post PLA 15 5 5 2 1 0 0.59 
 
Testing CNL 19 3 2 3 1 0 
 
  
CNH 15 8 3 1 0 1 
 
 
5 Pre PLA 25 3 0 0 0 0 0.55 
 
Testing CNL 26 1 1 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
5 Post PLA 18 4 5 1 0 0 0.89 
 
Testing CNL 17 5 4 1 1 0 
 
  
CNH 17 6 5 0 0 0 
 
 
6 Pre PLA 25 3 0 0 0 0 0.27 
 
Testing CNL 26 0 1 1 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
6 Post PLA 15 5 3 3 2 0 0.95 
 
Testing CNL 18 3 4 1 2 0 
 
  
CNH 17 3 4 3 1 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
 
  
 83 
 
Table 12: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Other 0 Pre  PLA 28 0 0 0 0 0 - 
Frequency Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
0 Post PLA 28 0 0 0 0 0 - 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
1 Pre PLA 28 0 0 0 0 0 - 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
1 Post PLA 28 0 0 0 0 0 - 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
5 Pre PLA 27 1 0 0 0 0 0.36 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
5 Post PLA 27 1 0 0 0 0 0.60 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
6 Pre PLA 27 1 0 0 0 0 0.36 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
6 Post PLA 28 0 0 0 0 0 - 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 13: Severity of side effects.               
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Dizziness 0 Pre  PLA 25 0 2 1 0 0 0.44 
Severity Testing CNL 23 4 0 1 0 0 
 
  
CNH 23 3 1 1 0 0 
 
 
0 Post PLA 24 3 0 1 0 0 0.53 
 
Testing CNL 22 4 0 1 1 0 
 
  
CNH 20 4 2 2 0 0 
 
 
1 Pre PLA 23 2 1 2 0 0 0.88 
 
Testing CNL 24 2 0 2 0 0 
 
  
CNH 22 3 1 1 0 1 
 
 
1 Post PLA 23 2 2 1 0 0 0.80 
 
Testing CNL 24 2 0 1 1 0 
 
  
CNH 22 2 2 2 0 0 
 
 
5 Pre PLA 23 1 2 1 0 0 0.45 
 
Testing CNL 24 4 0 1 0 0 
 
  
CNH 24 3 0 1 0 0 
 
 
5 Post PLA 24 2 0 2 0 0 0.64 
 
Testing CNL 23 3 1 1 0 0 
 
  
CNH 25 0 1 2 0 0 
 
 
6 Pre PLA 25 0 2 1 0 0 0.87 
 
Testing CNL 23 2 2 1 0 0 
 
  
CNH 25 1 1 1 0 0 
 
 
6 Post PLA 25 0 1 1 1 0 0.80 
 
Testing CNL 23 2 2 1 0 0 
 
  
CNH 24 2 1 1 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 13: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Headache 0 Pre  PLA 28 0 0 0 0 0 - 
Severity Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
0 Post PLA 26 1 0 1 0 0 0.54 
 
Testing CNL 27 0 0 1 0 0 
 
  
CNH 27 0 1 0 0 0 
 
 
1 Pre PLA 27 1 0 0 0 0 0.60 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
1 Post PLA 27 0 1 0 0 0 0.56 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
5 Pre PLA 28 0 0 0 0 0 - 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
5 Post PLA 27 0 1 0 0 0 0.56 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
6 Pre PLA 26 1 1 0 0 0 0.39 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
6 Post PLA 27 0 1 0 0 0 0.56 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 13: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Tachycardia 0 Pre  PLA 25 2 0 1 0 0 0.84 
Severity Testing CNL 23 4 0 1 0 0 
 
  
CNH 23 3 1 1 0 0 
 
 
0 Post PLA 25 2 1 0 0 0 0.87 
 
Testing CNL 23 3 2 0 0 0 
 
  
CNH 23 4 1 0 0 0 
 
 
1 Pre PLA 24 3 1 0 0 0 0.63 
 
Testing CNL 24 3 0 1 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
1 Post PLA 25 2 0 1 0 0 0.49 
 
Testing CNL 23 3 2 0 0 0 
 
  
CNH 25 2 0 1 0 0 
 
 
5 Pre PLA 26 1 0 1 0 0 0.52 
 
Testing CNL 24 3 1 0 0 0 
 
  
CNH 25 3 0 0 0 0 
 
 
5 Post PLA 25 1 2 0 0 0 0.44 
 
Testing CNL 23 4 1 0 0 0 
 
  
CNH 24 3 0 1 0 0 
 
 
6 Pre PLA 25 1 1 1 0 0 0.52 
 
Testing CNL 25 1 0 2 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
6 Post PLA 23 2 3 0 0 0 0.11 
 
Testing CNL 24 2 0 2 0 0 
 
  
CNH 27 0 0 1 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 13: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Heart 0 Pre  PLA 28 0 0 0 0 0 0.36 
Palpitations Testing CNL 28 0 0 0 0 0 
 Severity 
 
CNH 27 1 0 0 0 0 
 
 
0 Post PLA 27 1 0 0 0 0 0.73 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 26 1 1 0 0 0 
 
 
1 Pre PLA 28 0 0 0 0 0 0.40 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 27 0 1 0 0 0 
 
 
1 Post PLA 27 0 0 0 1 0 0.64 
 
Testing CNL 26 1 1 0 0 0 
 
  
CNH 25 1 1 1 0 0 
 
 
5 Pre PLA 27 1 0 0 0 0 0.36 
 
Testing CNL 26 2 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
5 Post PLA 27 0 0 1 0 0 0.53 
 
Testing CNL 25 2 1 0 0 0 
 
  
CNH 26 1 0 1 0 0 
 
 
6 Pre PLA 26 2 0 0 0 0 0.13 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
6 Post PLA 26 1 0 1 0 0 0.67 
 
Testing CNL 26 0 1 1 0 0 
 
  
CNH 27 0 0 1 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 13: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Dyspnea 0 Pre  PLA 24 1 2 1 0 0 0.66 
Severity Testing CNL 22 4 1 1 0 0 
 
  
CNH 24 1 1 2 0 0 
 
 
0 Post PLA 23 3 1 1 0 0 0.68 
 
Testing CNL 21 3 1 3 0 0 
 
  
CNH 21 1 3 3 0 0 
 
 
1 Pre PLA 23 1 1 1 2 0 0.61 
 
Testing CNL 24 1 1 2 0 0 
 
  
CNH 22 3 1 1 0 1 
 
 
1 Post PLA 22 1 3 1 1 0 0.52 
 
Testing CNL 23 2 1 2 0 0 
 
  
CNH 21 0 5 2 0 0 
 
 
5 Pre PLA 23 2 2 1 0 0 0.75 
 
Testing CNL 22 5 0 1 0 0 
 
  
CNH 23 3 1 1 0 0 
 
 
5 Post PLA 23 2 0 3 0 0 0.66 
 
Testing CNL 22 3 1 2 0 0 
 
  
CNH 24 0 1 3 0 0 
 
 
6 Pre PLA 25 1 1 1 0 0 0.83 
 
Testing CNL 22 2 1 3 0 0 
 
  
CNH 24 1 2 1 0 0 
 
 
6 Post PLA 24 1 0 2 1 0 0.66 
 
Testing CNL 22 1 2 3 0 0 
 
  
CNH 23 1 3 1 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 13: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Nervousness 0 Pre  PLA 28 0 0 0 0 0 - 
Severity Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
0 Post PLA 27 0 0 1 0 0 0.56 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 27 0 1 0 0 0 
 
 
1 Pre PLA 27 1 0 0 0 0 0.60 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
1 Post PLA 27 0 0 1 0 0 0.60 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 27 0 1 0 0 0 
 
 
5 Pre PLA 27 1 0 0 0 0 0.36 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
5 Post PLA 27 0 0 1 0 0 0.56 
 
Testing CNL 27 0 0 1 0 0 
 
  
CNH 27 0 1 0 0 0 
 
 
6 Pre PLA 27 0 1 0 0 0 0.36 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
6 Post PLA 27 0 0 1 0 0 0.56 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 27 0 1 0 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 13: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Blurred 0 Pre  PLA 25 2 0 1 0 0 0.83 
Vision Testing CNL 23 3 1 1 0 0 
 Severity 
 
CNH 24 2 0 2 0 0 
 
 
0 Post PLA 25 3 0 0 0 0 0.59 
 
Testing CNL 24 3 1 0 0 0 
 
  
CNH 23 5 0 0 0 0 
 
 
1 Pre PLA 24 3 1 0 0 0 0.64 
 
Testing CNL 24 3 0 1 0 0 
 
  
CNH 26 1 1 0 0 0 
 
 
1 Post PLA 26 2 0 0 0 0 0.58 
 
Testing CNL 24 4 0 0 0 0 
 
  
CNH 26 2 0 0 0 0 
 
 
5 Pre PLA 26 1 0 1 0 0 0.52 
 
Testing CNL 24 3 1 0 0 0 
 
  
CNH 25 3 0 0 0 0 
 
 
5 Post PLA 26 1 1 0 0 0 0.43 
 
Testing CNL 24 4 0 0 0 0 
 
  
CNH 25 3 0 0 0 0 
 
 
6 Pre PLA 25 1 1 1 0 0 0.52 
 
Testing CNL 25 2 0 1 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
6 Post PLA 24 2 2 0 0 0 0.36 
 
Testing CNL 25 2 1 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Table 13: Continued.             
   
Rating of Symptom 
 Symptom Day Treatment 0 1 2 3 4 5 Chi-Square 
Other 0 Pre  PLA 28 0 0 0 0 0 - 
Severity Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
0 Post PLA 28 0 0 0 0 0 0.36 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
1 Pre PLA 28 0 0 0 0 0 0.40 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 27 0 1 0 0 0 
 
 
1 Post PLA 28 0 0 0 0 0 0.52 
 
Testing CNL 27 1 0 0 0 0 
 
  
CNH 25 1 1 1 0 0 
 
 
5 Pre PLA 26 1 1 0 0 0 0.39 
 
Testing CNL 26 2 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
5 Post PLA 28 0 0 0 0 0 0.36 
 
Testing CNL 26 2 0 0 0 0 
 
  
CNH 27 1 0 0 0 0 
 
 
6 Pre PLA 25 1 1 1 0 0 0.40 
 
Testing CNL 28 0 0 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 
 
6 Post PLA 27 1 0 0 0 0 0.40 
 
Testing CNL 27 0 1 0 0 0 
 
  
CNH 28 0 0 0 0 0 
 Data are presented as frequency. Statistical significance is detailed from chi-squared analysis. p < 0.05 considered significant. 
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Secondary Outcome Variables – Performance 
Bench Press and Leg Press Performance 
Table 14 presents bench and leg press performance. MANOVA analysis revealed 
overall Wilks’ Lambda treatment (p=0.94), time (p=0.001), sex (p=0.001), treatment x 
time (p=0.11), treatment x sex (p=0.90), time x sex (p=0.001), and treatment x time x 
sex (p=0.57). Univariate analysis revealed significant time effects for bench press 1RM 
(p=0.001), maximum number of repetitions at 70% 1RM on bench press (p=0.001), and 
leg press 1RM (p=0.001), sex effects for bench press 1RM (p=0.001), maximum number 
of repetitions at 70% 1RM on bench press (p=0.04), and leg press 1RM (p=0.01), time x 
sex effects for bench press 1RM (p=0.001) and treatment x time x sex effects for 
maximum number of repetitions at 70% 1RM on leg press (p=0.038). No other 
significant differences were found among bench press or leg press performance.  
Figures 18 through 21 present the mean change from baseline with 95% CI;s in 
bench press 1RM, maximum number of repetitions at 70% 1RM on bench press, leg 
press 1RM, and maximum number of repetitions at 70% 1RM on leg press, respectively. 
Analysis of mean changes from baseline with 95% CI revealed the change in bench 
press 1RM was significantly lower than baseline for all treatments at day 0 post 
supplement (p < 0.05), significantly higher for only CNH at day 5 pre supplementation 
(p < 0.05), and significantly lower for PLA and CNL, but not CNH, at day 5 post 
supplementation (PLA: -4.2 [-5.7, -2.7], CNL: -4.2 [-5.7, -2.7], CNH: -1.8 [-3.3, -0.3], 
p=0.01). The change in leg press 1RM was significantly lower than baseline for all 
treatments at day 0 post supplement (p<0.05) and significantly lower for PLA and CNL, 
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but not CNH, at day 5 post supplementation (PLA: -13.9 [-23.1, -4.7], CNL: -13.2 [-
22.3, -4.0], CNH: -6.0 [-15.2, 3.1], p=0.01). Pairwise comparisons also found a 
significant difference between CNH and PLA, but not CNL at day 5 pre supplementation 
(PLA: 0.3 [-0.8, 1.5], CNL: 0.9 [-0.3, 2.1], CNH: 2.8 [1.6, 3.9], p=0.01). No other 
differences were found among treatments for bench press or leg press performance. 
These data reject H05: There will be no significant difference among treatments in bench 
press or leg press performance. 
4-K Time Trial Cycle Ergometer Performance 
Table 15 presents 4-K time trial cycle ergometer performance. MANOVA 
analysis revealed overall Wilks’ Lambda treatment (p=0.79), time (p=0.008), sex 
(p=0.001), treatment x time (p=0.20), treatment x sex (p=0.85), time x sex (p=0.22), and 
treatment x time x sex (p=0.06). Univariate analysis revealed significant sex (p=0.001) 
and treatment x time x sex (p=0.02) for time to completion and time (p=0.005) and sex 
(p=0.001) for mean power. No other significant differences were found in 4-K time trial 
performance. 
Figure 22 presents the change in 4-K time trial time and figure 23 presents the 
change in 4-K time trial power. Analysis of mean changes from baseline with 95% CI 
revealed PLA was significantly higher at day 6 post supplement compared to baseline 
for the change in 4-K time trial power (p = 0.005). No other differences were found for 
4-K Time Trial Performance. These data fail to reject H06: There will be no significant 
differences among treatments in cycle ergometer performance.  
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Table 14: Bench Press & Leg Press performance.             
  
Day 
    Variable Treatment 0 Pre 0 Post 5 Pre 5 Post Mean Interaction p-Level 
BENCH PRESS PERFORMANCE 
    1-Repetition Overall 74.0±30.1 68.0±28.5* 75.3±30.4* 70.6±29.0* 71.9±29.4 Time 0.001 
Maximum PLA 74.5±30.7 68.1±28.3 74.8±30.4 70.3±29.2 72.5±29.1 Treatment 0.93 
(KG) CNL 73.2±29.8 67.1±28.3 74.1±30.2 69.0±28.7 70.4±28.8 Treatment x Time 0.46 
 
CNH 74.2±30.7 68.8±29.7 77.0±31.6 72.4±30.1 73.0±30.7 
   
 
Male 92.6±19.9 84.5±21.2* 93.9±20.6* 87.7±21.1* 89.3±21.0 Sex 0.001 
 
Female 40.5±7.7† 38.3±8.4†* 41.9±8.9†* 39.7±7.6† 40.0±8.6† Time x Sex 0.001 
 
PLA M 92.9±21.2 84.1±21.7 92.9±21.2 87.0±22.1 88.9±21.2 Treatment x Sex 0.95 
 
PLA F 41.4±9.5 39.3±9.1 42.3±9.9 40.2±8.2 41.0±9.3 Treatment x Time x Sex 0.96 
 
CNL M 91.5±19.7 83.5±21.1 92.3±20.6 85.9±20.8 87.3±20.8 
   
 
CNL F 40.2±6.8 37.5±7.5 41.4±8.6 38.6±7.1 39.4±7.8 
   
 
CNH M 93.2±20.0 86.0±22.1 96.3±20.8 90.3±21.3 91.7±21.2 
    CNH F 40.0±7.4 38.0±9.2 42.1±8.9 40.2±8.1 39.7±8.6    
Maximum Number Overall 14.1±5.3 14.1±4.7 14.7±5.0 15.5±5.3* 14.3±5.1 Time 0.006 
of Repetitions PLA 14.8±5.9 14.0±5.0 14.7±5.6 15.6±6.3 14.8±5.8 Treatment 0.55 
(70%  CNL 12.9±4.0 14.0±4.4 14.1±4.6 14.9±4.5 13.5±4.1 Treatment x Time 0.76 
1-RM) CNH 14.8±5.6 14.2±4.9 15.3±4.9 15.9±4.9 14.7±5.2 
   
 
Male 13.7±4.8 13.2±4.7 14.1±4.9 14.5±5.2 13.5±4.9 Sex 0.04 
 
Female 14.9±6.0 15.6±4.4 15.9±5.2 17.2±4.9 15.8±5.3† Time x Sex 0.34 
 
PLA M 13.4±4.6 12.7±4.7 12.9±3.9 14.0±5.2 13.0±4.5 Treatment x Sex 0.26 
 
PLA F 17.2±7.4 16.4±5.0 18.0±6.8 18.6±7.2 18.3±6.5 Treatment x Time x Sex 0.62 
 
CNL M 12.6±4.4 13.3±5.0 13.7±5.3 14.3±5.2 13.0±4.7 
   
 
CNL F 13.4±3.3 15.1±3.3 14.7±3.1 16.0±2.6 14.2±2.7 
   
 
CNH M 15.2±5.3 13.5±4.8 15.6±5.1 15.3±5.5 14.6±5.3 
    CNH F 14.0±6.3 15.4±5.1 14.9±4.8 17.1±3.7 14.8±5.0    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.94), time (p=0.001), sex (p=0.001), treatment x time (p=0.11), treatment x 
sex (p=0.90), time x sex (p=0.001), and treatment x time x sex (p=0.57). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. 
p<0.05 is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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Table 14: Continued.           
  
Day 
    Variable Treatment 0 Pre 0 Post 5 Pre 5 Post Mean Interaction p-Level 
LEG PRESS PERFORMANCE 
       1-Repetition Overall 408±123 391±121* 417±124* 397±122* 403±119 Time 0.001 
Maximum PLA 411±122 397±119 417±125 397±117 407±115 Treatment 0.66 
(KG) CNL 397±122 379±119 404±122 384±120 387±114 Treatment x Time 0.62 
 
CNH 417±129 399±128 428±127 411±132 414±127 
   
 
Male 476±96 456±98 483±98 464±97 466±94 Sex 0.001 
 
Female 286±51 276±50 297±55 278±48 287±54† Time x Sex 0.38 
 
PLA M 474±99 457±99 479±105 461±92 464±95 Treatment x Sex 0.88 
 
PLA F 296±59 288±61 305±63 282±46 299±58 Treatment x Time x Sex 0.97 
 
CNL M 464±95 443±94 470±95 449±96 448±90 
   
 
CNL F 278±53 262±44 285±53 268±50 275±52 
   
 
CNH M 491±96 467±104 500±96 482±106 485±96 
    CNH F 285±45 276±47 300±52 283±52 286±50    
Maximum Number Overall 20.8±7.7 20.3±8.1 21.5±7.7 21.8±7.4 21.3±7.7 Time 0.06 
of Repetitions PLA 21.8±9.3 20.5±8.7 21.4±8.2 21.7±8.2 21.8±8.5 Treatment 0.70 
(70%  CNL 19.0±7.3 18.9±7.8 21.1±8.3 21.4±7.2 20.2±7.8 Treatment x Time 0.23 
1-RM) CNH 21.6±5.9 21.4±7.9 22.0±6.7 22.4±6.7 21.9±6.7 
   
 
Male 21.6±7.2 20.6±6.3 21.8±6.9 22.5±6.5 21.4±6.9 Sex 0.35 
 
Female 19.3±8.3 19.7±10.6 20.9±9.0 20.6±8.6 21.2±9.1 Time x Sex 0.56 
 
PLA M 21.7±9.1 20.2±6.1 20.8±6.4 22.6±7.3 21.2±7.5 Treatment x Sex 0.72 
 
PLA F 21.9±10.3 21.0±12.4 22.3±11.1 20.1±10.0 22.9±10.2 Treatment x Time x Sex 0.04 
 
CNL M 19.9±6.5 19.9±6.3 20.7±7.6 21.8±5.4 20.3±6.6 
   
 
CNL F 17.5±8.7 17.0±9.9 21.8±9.7* 20.7±10.1 20.1±9.8 
   
 
CNH M 23.3±5.7 21.6±6.8 23.9±6.4 23.2±7.1 22.7±6.6 
    CNH F 18.5±5.4 21.1±10.0 18.5±6.0 21.1±6.1 20.6±6.8    
Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.94), time (p=0.001), sex (p=0.001), treatment x time (p=0.11), treatment x 
sex (p=0.90), time x sex (p=0.001), and treatment x time x sex (p=0.57). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. 
p<0.05 is considered significant. Statistical notations. (*) denotes a significant difference from baseline. (†) denotes a significant difference from male. 
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        Figure 18. Changes in bench press one repetition maximum. Data are means ± CI. p<0.05 is considered 
significant. Statistical notations. (a) denotes a significant difference from PLA. (b) denotes a significant 
difference from CNL. (c) denotes a significant difference from CNH. (*) denotes a significant difference 
from baseline. 
 
 
 
 
       
        
        
        
        
        
        
        
        
        
        
        
        
        
        Figure 19. Changes in bench press repetitions to fatigue @ 70% 1RM. Data are means ± CI. p<0.05 is 
considered significant.  
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        Figure 20. Changes in leg press one repetition maximum. Data are means ± CI. p<0.05 is considered 
significant. Statistical notations.  (*) denotes a significant difference from baseline. 
 
 
 
 
       
        
        
        
        
        
        
        
        
        
        
        
        
        
        Figure 21. Changes in leg press repetitions to fatigue @ 70% 1RM. Data are means ± CI. p<0.05 is 
considered significant.  
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Table 15: 4-K Time Trial Cycle Ergometer Performance.       
  
Day 
   
 
  Treatment 1 6 Mean Interaction p-Level 
Time Overall 275±103 270±110 272±106 Time 0.34 
(secs) PLA 271±100 263±105 267±102 Treatment 0.45 
 
CNL 282±99 286±122 284±110 Treatment x Time 0.07 
 
CNH 271±113 262±105 267±108 
   
 
Male 210±35 204±36 207±35 Sex 0.001 
 
Female 391±79 390±98 390±88† Time x Sex 0.47 
 
PLA M 212±35 201±36 207±35 Treatment x Sex 0.73 
 
PLA F 378±89† 374±98† 376±91 Treatment x Time x Sex 0.02 
 
CNL M 220±37 214±39 217±38 
   
 
CNL F 392±75† 416±114†* 404±95 
   
 
CNH M 198±32 197±31 197±31 
    CNH F 402±80† 381±85†* 392±81    
Mean Power Overall 245±80 253±86* 249±83 Time 0.005 
(W) PLA 246±79 258±86 252±82 Treatment 0.55 
 
CNL 237±74 242±85 240±79 Treatment x Time 0.47 
 
CNH 252±88 260±87 256±87 
   
 
Male 293±55 304±59 299±57 Sex 0.001 
 
Female 159±27 162±32 160±29† Time x Sex 0.10 
 
PLA M 291±57 308±62 300±59 Treatment x Sex 0.72 
 
PLA F 165±31 168±33 167±31 Treatment x Time x Sex 0.30 
 
CNL M 282±49 291±61 286±55 
   
 
CNL F 157±26 153±35 155±30 
   
 
CNH M 306±57 313±56 310±56 
   
 
CNH F 154±25 163±30 159±27 
   Data are means ± SD. MANOVA analysis revealed overall Wilks' Lambda treatment (p=0.79), time (p=0.008), sex 
(p=0.001), treatment x time (p=0.20), treatment x sex (p=0.85), time x sex (p=0.22), and treatment x time x sex 
(p=0.06). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. p<0.05 is 
considered significant. Statistical notations.  (*) denotes a significant difference from baseline. (†) denotes a 
significant difference from male. 
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        Figure 22. Changes in 4-K time trial time. Data are means ± CI. p<0.05 is considered significant. 
Statistical notations. (*) denotes a significant difference from baseline. 
 
 
 
 
       
        
        
        
        
        
        
        
        
        
        
        
        
        
        Figure 23. Changes in 4-K time trial power. Data are means ± CI. p<0.05 is considered significant. 
Statistical notations. (*) denotes a significant difference from baseline. 
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
  
Creatine and nitrates are popular dietary supplements, but little is known 
regarding their co-ingestion relative to performance, side effects, and safety. Only two 
previous studies [42,43] have examined creatine nitrate alone and two other studies 
[44,45] have examined creatine nitrate as a part of a multiple ingredient supplement. 
Each of these studies found that creatine nitrate appears to be safe for the dose (1-3 
grams per day) and duration (up to 8 weeks) examined. The current study examined low 
(3 grams per day) and high (6 grams per day) dose creatine nitrate supplementation 
compared to a placebo (6 grams of glucose per day) over a 7 day period with multiple 
strenuous exercise bouts on hemodynamic changes, clinical health markers, exercise 
performance, hydration status, and reported side effects. The results of the present study 
support 7 days of creatine nitrate supplementation as apparently safe while undergoing 
strenuous exercise and may provide a performance enhancing benefit. 
As expected, significant time effects in diastolic blood pressure, pulse pressure, 
heart rate, and rate pressure product and the change in DBP, PP, HR, and RPP, but not 
systolic blood pressure or mean arterial pressure, or the change in SBP or MAP, were 
observed in this study. Research shows little change in systolic blood pressure, but an 
increase in diastolic blood pressure and heart rate when comparing supine to standing 
positions [140]. Prior research has generally shown an increase in heart rate post-
exercise compared to pre-exercise [141]. Our findings in this study support both of the 
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positional changes and the post exercise changes to blood pressure and heart rate. While 
nitrate supplementation studies have found decreases in blood pressure after 
supplementation [102,103,106-108], studies examining creatine nitrate, as part of a 
multi-ingredient supplement [44,45] or independently [42,43] have not found similar 
results. In a meta-analysis, Siervo et al. [142] found a significant decrease in SBP (-4.4 
mm Hg 95% CI [-5.9, -2.8] p<0.001), but not DBP (-1.1 mm Hg 95% CI [-2.2, 0.1] 
p=0.06) from beetroot juice and inorganic nitrate supplementation. Sixteen crossover 
studies were included in the analysis with supplementation durations ranging from 2 
hours to 15 days and washout periods ranging from 6 to 28 days. The dose of nitrate 
ranged from ~150 mg to ~3 grams per day. Nine of the studies asked their participants to 
not consume foods high in nitrate before the study and six asked their participants to not 
change their regular diet. Out of the sixteen studies, six (38%) found no change in SBP 
and 9 (56%) found no change in DBP, equally distributed among the studies which 
controlled and did not control for dietary nitrate. Neither the duration of supplementation 
or source of nitrate were found to be associated with decreased blood pressure, but a 
meta-regression found a significant (p<0.5) correlation between dose of nitrate and 
decrease in SBP.  Our study is in agreement with the other creatine nitrate studies, where 
no treatment effects were found for SBP, DBP, MAP, PP, HR, or RPP. Additionally, no 
changes in hemodynamic reactivity were found among treatments or over time. While 
dietary nitrates may relate to an important mechanism of blood pressure regulation in the 
body, adding additional nitrates through creatine nitrate (up to 2 grams per day for 6 
days) on top of those supplied by the diet (0.12 – 1.2 grams per day) appears to not 
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produce a significant blood pressure lowering effect. These data show high doses of 
creatine nitrate (6 grams, 2 grams nitrate per day) for 6 days do not pose a risk of 
hypotension while undergoing strenuous exercise. 
In our study, the assessment of blood chemistry changes found no significant 
differences among treatments changing from normal clinical values to above normal 
clinical values for any of the blood chemistry parameters measured. Likewise, no 
differences among treatments were found in hydration status and no differences among 
treatments were reported for the frequency or severity of any side effect. In agreement 
with other creatine nitrate studies [42-45] and based on these findings we conclude 
creatine nitrate supplementation is apparently safe and well-tolerated at 6 grams per day 
for 6 days. 
While significant time effects were found for the performance variables, no 
significant treatment or treatment x time interactions were found. Although no 
significant time x treatment interactions were observed, analysis of mean changes from 
baseline with 95% CI revealed bench press 1RM was significantly lower than baseline 
for all treatments at day 0 post supplement (p < 0.05), significantly higher for only CNH 
at day 5 pre supplementation (p < 0.05) with a significant difference between CNH and 
PLA, but not CNL (PLA: 0.3 [-0.8, 1.5], CNL: 0.9 [-0.3, 2.1], CNH: 2.8 [1.6, 3.9], 
p=0.01), and significantly lower for PLA and CNL, but not CNH, at day 5 post 
supplementation (PLA: -4.2 [-5.7, -2.7], CNL: -4.2 [-5.7, -2.7], CNH: -1.8 [-3.3, -0.3], 
p=0.01). The change in leg press 1RM was significantly lower than baseline for all 
treatments at day 0 post supplement (p<0.05) and significantly lower for PLA and CNL, 
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but not CNH, at day 5 post supplementation (PLA: -13.9 [-23.1, -4.7], CNL: -13.2 [-
22.3, -4.0], CNH: -6.0 [-15.2, 3.1], p=0.01). No significant effects among groups were 
found for the 4K time trial. No significant differences in performance among treatments 
were expected due to the dose and duration of creatine supplementation. Typical, acute 
dosages of creatine are ~20 grams per day for 5 days, followed by a maintenance dose of 
3-5 grams per day, whereas, our study provided 3 or 6 grams of creatine nitrate per day, 
which provides 2 and 4 grams of creatine per day, for seven days. Galvan et al [42] 
demonstrated muscle creatine concentrations were not significantly elevated after 7 days 
of 6 grams per day of creatine nitrate, but were after 12 grams per day of creatine nitrate. 
Also, a dose of 3 grams per day of creatine nitrate for 21 days was not sufficient to 
maintain the elevated creatine concentrations. Based on this data and our findings, the 
dosage of creatine supplied by the creatine nitrate used in our study was probably too 
low to induce a performance enhancing effect.  
On the other hand, a few studies have shown improvements in power related 
activities due to nitrate supplementation (0.25 - 0.5 grams) in sub-maximal performance 
[110,114] and recovery [111,113]. In a double-blind, randomized, crossover study, 
Thompson et al. [143] gave participants 70 ml of concentrated beetroot juice (400 mg of 
nitrate) per day for 5 days. After the supplementation period, participants were tested on 
a series of 5 x 20 m sprints and a repeated sprint interval test. The average split times for 
the 20 m sprint tests were 2.3% at 5 m, 1.6% at 10 m, and 1.2% at 20 m higher in the 
beetroot juice treatment compared to placebo and the beetroot juice treatment was able 
to cover 3.9% more distance in the repeated sprint interval test. Wylie et al. [144] found 
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similar results, 4.2% improvement in the sprint interval test, while supplementing with 7 
x 70 ml doses of beetroot juice (totaling ~1750 mg of nitrate) spread over 24 hours 
before testing.  
In a series of tests, Clifford et al. [111,113] demonstrated beetroot juice could be 
used to improve recovery from an intense exercise bout. In the first study [111], 
participants performed 100 drop jumps and immediately consumed either 3 x 250 ml of 
beetroot juice (250 mg of nitrate), 3 x 125 ml of beetroot juice (125 mg of nitrate), or 
250 ml of placebo. At 24 and 48 hours post exercise participants consumed another 2 
servings of their assigned supplement. Counter movement jump performance recovered 
more quickly in the 250 ml beetroot juice group compared to placebo at both 48 (92% 
vs. 74% of baseline) and 72 (93% vs. 86% of baseline) hours post exercise. In the second 
study [113], participants performed 20 x 30 m repeated sprints, followed by 2 doses of 
250 ml of beetroot juice (250 mg of nitrate) or placebo immediately, at 24 and 48 hours, 
then another round of 20 x 30 m sprints at 72 hours, immediately followed by 2 more 
doses of 250 ml of beetroot juice. Both counter movement jump (7.6%) and reactive 
strength index (13.8%) recovered more quickly for the beetroot juice group compared to 
placebo at 72 hours.  
In a randomized, double-blind, crossover study, Mosher et al. [114] gave 
participants either 70 ml of concentrated beetroot juice (400 mg of nitrate) or placebo 
each day for 6 days with a 72 hour washout between treatments. After supplementation, 
participants performed 3 sets to failure at 60% of their 1RM on bench press. During the 
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beetroot juice treatment participants performed 19.4% more repetitions and lifted 18.9% 
more total weight compared to placebo.  
Oliveiro et al. [145], in a randomized, double-blind, crossover design, showed a 
beetroot gel (750 mg of nitrate) can improve the recovery of handgrip maximal 
voluntary contraction force (MVC) in elderly participants. After baseline MVC was 
collected participants consumed either the beetroot gel or a placebo and waited 150 
minutes, after which, participants performed 1 set at 30% of their MVC for one minute. 
Twenty minutes post exercise the beetroot gel group significantly recovered more than 
the placebo group (-18.56±13.8, -26.18±14.6 N; P<0.05). Our study is in agreement with 
these studies showing improved recovery after strenuous exercise, adding creatine nitrate 
may improve maximal strength after acute supplementation. 
In conclusion, 3-6 grams of creatine nitrate consumed while undergoing 
strenuous physical activity appears to be safe for the durations studied based on 
hemodynamic and clinical measures. A ~4% improvement in bench press 1RM was 
found with improved recovery post exercise on bench press and leg press 1RM, with no 
change in repetitions to fatigue, or cycle ergometry performance. Previous studies have 
shown chronic creatine nitrate supplementation is effective at improving the benefit 
induced by strength training (~8% compared to placebo) [42]. More research is needed 
to determine optimal loading and maintenance doses of creatine nitrate for performance 
enhancement. While much research has focused on the benefit nitrates may have on 
endurance performance, further research into the strength enhancing effects of nitrate 
supplementation is also warranted.  
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